[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8991
1. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics. Int J Toxicol; 2005;24 Suppl 2:21-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acrylamide was a tumor initiator, but not an initiator/promoter, in two different mouse strains at a total dose of 300 mg/kg (6 doses over 2 weeks) resulting in increased lung adenomas and carcinomas without promotion.
  • In one study, increased incidence of mammary gland tumors, glial cell tumors, thyroid gland follicular tumors, oral tissue tumors, uterine tumors and clitoral gland tumors were noted in female rats.
  • In male rats, the number of tumors in the central nervous system (CNS), thyroid gland, and scrotum were increased with acrylamide exposure.
  • In the second study, using higher doses and a larger number of female rats, glial cell tumors were not increased, nor was there an increase in mammary gland, oral tissue, clitoral gland, or uterine tumors.
  • Tumors of the scrotum in male rats were confirmed, as were the thyroid gland follicular tumors in males and females.
  • Although there are mechanisms of action of acrylamide that have been proposed for tumor types seen in rat studies that suggest they may be unique to the rat, the Panel was not convinced that these results could be disregarded as a species-specific finding with no relevance to human health and safety.

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • Hazardous Substances Data Bank. POLYACRYLAMIDE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154914.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Acrylic Resins; 0 / Cosmetics; 0 / Irritants; 0 / Teratogens; 9003-05-8 / polyacrylamide
  • [Number-of-references] 99
  •  go-up   go-down


2. Cairncross G, Jenkins R: Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J; 2008 Nov-Dec;14(6):352-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
  • Today, treatment recommendations for patients with all types of gliomas are based on light microscopic evaluation of tumor tissue with no allowance for genetic variability.
  • Surgery improves symptoms, especially headache or seizures, and radiotherapy controls tumor growth for most patients.
  • That said, the recognition that oligodendrogliomas with 1p/19q loss are sensitive to current therapies and slowly growing is already influencing our management of patients with this type of glioma, spawning trials in which patients are selected by molecular signature.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060598.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 29
  •  go-up   go-down


3. Arbab AS: Cytotoxic T-cells as imaging probes for detecting glioma. World J Clin Oncol; 2010 Nov 10;1(1):3-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cells as imaging probes for detecting glioma.
  • Tumor vaccination using tumor-associated antigen-primed dendritic cells (DCs) is in clinical trials.
  • Investigators are using patients' own immune systems to activate T-cells against recurrent or metastatic tumors.
  • Following vaccination of DCs or attenuated tumor cells, clinical as well as radiological improvements have been noted due to migration and accumulation of cytotoxic T-cells (CTLs).
  • CTLs mediated tumor cell killing resulted in extended survival in clinical trails and in preclinical models.
  • Besides administration of primed DCs or attenuated or killed tumors cells to initiate the generation of CTLs, investigators have started making genetically altered T-cells (CTLs) to target specific tumors and showed in vivo migration and accumulation in the implanted or recurrent tumors using different imaging modalities.
  • Our groups have also showed the utilization of both in vivo and in vitro techniques to make CTLs against glioma and used them as imaging probes to determine the sites of tumors.
  • In this short review, the current status of vaccination therapy against glioma and utilization of CTLs as in vivo imaging probes to determine the sites of tumors and differentiate recurrent glioma from radiation necrosis will be discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2009 Jan;49(1):124-32 [18980227.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2742-9 [12171908.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Vaccine. 2003 Jan 30;21(7-8):791-4 [12531361.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):109-14 [12712005.001]
  • [Cites] Int J Oncol. 2003 Jul;23(1):5-15 [12792771.001]
  • [Cites] Cancer Immunol Immunother. 2004 Apr;53(4):363-72 [14605763.001]
  • [Cites] J Immunother. 2004 Mar-Apr;27(2):147-55 [14770086.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):571-7 [15160996.001]
  • [Cites] Scand J Immunol. 2004 Nov;60(5):506-13 [15541044.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):162-8 [15598955.001]
  • [Cites] Bull Cancer. 2005 Apr;92(4):333-42 [15888390.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5566-71 [16061874.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jan;56(1):1-12 [16676183.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E4 [16709035.001]
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):499-511 [16971806.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3343-50 [12947071.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Folia Biol (Praha). 2003;49(4):147-59 [12971584.001]
  • [Cites] J Immunother. 2003 Sep-Oct;26(5):432-9 [12973032.001]
  • [Cites] Neuroradiology. 1992;34(6):463-9 [1436452.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1172-9 [14520441.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6838-46 [14583481.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-75 [17255279.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):519-26 [17763342.001]
  • [Cites] J Immunother. 2007 Oct;30(7):749-61 [17893567.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):849-55 [17999605.001]
  • [Cites] Methods Mol Biol. 2008;423:139-53 [18370195.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3832-9 [18559603.001]
  • [Cites] Vaccine. 2009 Jan 22;27(4):558-64 [19027812.001]
  • [Cites] BMC Cancer. 2008;8:360 [19055839.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273 [19214609.001]
  • [Cites] Cancer Biol Ther. 2009 May;8(10):973-80 [19287216.001]
  • [Cites] PLoS One. 2009;4(6):e5873 [19517015.001]
  • [Cites] Cytotherapy. 2009;11(5):653-68 [19530029.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1818-24 [19609282.001]
  • [Cites] Brain Pathol. 2009 Oct;19(4):694-712 [19744041.001]
  • [Cites] Cell Immunol. 2009;260(1):56-62 [19818956.001]
  • [Cites] Vaccine. 2009 Dec 11;28(2):542-7 [19837091.001]
  • [Cites] J Neurosurg. 2010 Aug;113(2):270-9 [19895199.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):250-61 [2644399.001]
  • [Cites] Clin Endocrinol (Oxf). 1983 Jul;19(1):111-6 [6413098.001]
  • [Cites] Invest Urol. 1980 May;17(6):451-3 [6768694.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1297-302 [7489412.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3290-8 [9531286.001]
  • [Cites] Invest Radiol. 1978 Mar-Apr;13(2):121-6 [96041.001]
  • [Cites] Cancer Invest. 2003;21(6):873-86 [14735692.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jun 15;169(12):1322-30 [15070823.001]
  • [Cites] Clin J Oncol Nurs. 2004 Aug;8(4):368-76 [15354923.001]
  • [Cites] J Exp Ther Oncol. 2006;5(3):183-93 [16528969.001]
  • [Cites] Neurol Res. 1991 Mar;13(1):48-54 [1675447.001]
  • [Cites] Int Immunol. 2003 Oct;15(10):1265-73 [13679395.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):125-34 [14600790.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jul;57(7):1029-38 [18157497.001]
  • [Cites] J Transl Med. 2008;6:6 [18221542.001]
  • [Cites] Clin Vaccine Immunol. 2008 Sep;15(9):1337-44 [18667638.001]
  • [Cites] G Ital Dermatol Venereol. 2008 Aug;143(4):235-50 [18833080.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Jan;6(1):53-8 [19015650.001]
  • [Cites] Eur J Haematol. 1989 Mar;42(3):276-83 [2494057.001]
  • [Cites] Clin Nucl Med. 1985 Jan;10(1):30-4 [3919985.001]
  • [Cites] In Vivo. 1993 Jan-Feb;7(1):27-30 [8504205.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:359-62; discussion 362-3 [11458523.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):1-14 [18719915.001]
  • (PMID = 21603304.001).
  • [ISSN] 2218-4333
  • [Journal-full-title] World journal of clinical oncology
  • [ISO-abbreviation] World J Clin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122031-03; United States / NCI NIH HHS / CA / CA129801-02; United States / NCI NIH HHS / CA / R21 CA129801; United States / NCI NIH HHS / CA / R01 CA122031-03; United States / NCI NIH HHS / CA / R01 CA122031; United States / NCI NIH HHS / CA / R21 CA129801-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS222117; NLM/ PMC3095453
  • [Keywords] NOTNLM ; Cellular magnetic resonance imaging / Cytotoxic T-cells / Glioma / Glioma associated antigen / Imaging probes / Magnetic resonance imaging / Tumor vaccine
  •  go-up   go-down


Advertisement
4. Petrás M, Hutóczki G, Varga I, Vereb G, Szöllosi J, Bognár L, Ruszthi P, Kenyeres A, Tóth J, Hanzély Z, Scholtz B, Klekner A: [Expression pattern of invasion-related molecules in brain tumors of different origin]. Magy Onkol; 2009 Sep;53(3):253-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression pattern of invasion-related molecules in brain tumors of different origin].
  • Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of radical surgical resection and successful treatment, with tumor recurrence as microdisseminated disease.
  • Epidermal growth factor receptors (EGFRs), integrins and their ligands in the extracellular matrix (ECM) predominantly participate in the invasion process, including the cell adhesion to the surrounding microenvironment and cell migration.
  • The extent of infiltration of the surrounding brain tissue by malignant tumors strongly depends on the tumor cell type.
  • Malignant gliomas show much more intensive peritumoral invasion than do metastatic tumors.
  • In this study, the mRNA expression of 29 invasion-related molecules (18 cell membrane receptors or receptor subunits (EGFRs and integrins) and 11 ECM components: collagens, laminins and fibronectin) was investigated by quantitative reverse transcriptase-polymerase chain reaction.
  • Determining the differences in invasion-related molecules in tumors of different origin can help identify the exact molecular mechanisms that facilitate peritumoral infiltration by glioblastoma cells.
  • These results should allow the selection of target molecules for potential chemotherapeutic agents directed against highly invasive malignant gliomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Actins / analysis. Amino Acids, Diamino / analysis. Collagen / analysis. Fibronectins / analysis. Glioblastoma / metabolism. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / analysis. Humans. Immunohistochemistry. Integrin alpha Chains / analysis. Integrin beta Chains / analysis. Ki-67 Antigen / analysis. Neoplasm Invasiveness. RNA, Messenger / analysis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptor, ErbB-3 / analysis. Receptor, ErbB-4

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793689.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Actins; 0 / Amino Acids, Diamino; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Integrin alpha Chains; 0 / Integrin beta Chains; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 2408-79-9 / laminine; 9007-34-5 / Collagen; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


5. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, Ballman KV: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J Neurooncol; 2007 Sep;84(3):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.
  • METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.
  • We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.
  • Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):577-82; discussion 582 [8008153.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • (PMID = 17431544.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Park SM, Kim HS, Jahng GH, Ryu CW, Kim SY: Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T. Br J Radiol; 2010 Jun;83(990):466-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two observers categorised tumours as glial or non-glial tumours, and then subcategorised the gliomas into low-grade or high-grade tumours.
  • The sensitivity, specificity, positive predictive value and negative predictive value for glioma grading with the non-contrast protocol were 83.2%, 100%, 100% and 79.3%, respectively.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pathol. 2000 Oct;20(5):413-28 [11084409.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):496-520 [11276094.001]
  • [Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Invest Radiol. 2003 Jul;38(7):409-14 [12821854.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] Magn Reson Med. 2004 Sep;52(3):612-8 [15334582.001]
  • [Cites] Radiology. 1984 Feb;150(2):435-40 [6691098.001]
  • [Cites] Radiology. 1997 Jul;204(1):272-7 [9205259.001]
  • [Cites] Neuroradiology. 1997 Jul;39(7):483-9 [9258924.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):736-42 [15814914.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Rofo. 2005 Aug;177(8):1065-9 [16021537.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):439-50 [16163700.001]
  • [Cites] J Magn Reson Imaging. 2006 Jul;24(1):41-51 [16755540.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Aug;28(7):1280-6 [17698528.001]
  • [Cites] Neuroradiology. 2008 Jan;50(1):9-16 [17876570.001]
  • (PMID = 19690076.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3473590
  •  go-up   go-down


7. Amano S, Li S, Gu C, Gao Y, Koizumi S, Yamamoto S, Terakawa S, Namba H: Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol; 2009 Dec;35(6):1265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy.
  • In our previous study, we successfully treated an established C6 brain tumor using neural stem cells transduced with the herpes simplex virus-thymidine kinase gene (HSVtk) and ganciclovir in the rat.
  • Those cells were used for in vitro co-culture study and in vivo co-implantation study with C6 rat glioma cells to examine bystander tumoricidal effect, which revealed a sufficient bystander effect and only 1/32 MSCtk cells were needed for complete tumor eradication.
  • In vitro bystander effect was also observed in a real-time fashion using a culture microscope and it was shown that only tumor cells that had contact with MSCtk cells died.
  • In vivo treatment study of an established C6 brain tumor with an intratumoral injection of MSCtk cells followed by systemic ganciclovir administration demonstrated a significant reduction of the tumor size and a significant survival prolongation.
  • [MeSH-major] Antiviral Agents / therapeutic use. Brain Neoplasms / therapy. Ganciclovir / therapeutic use. Genetic Therapy / methods. Glioma / therapy. Mesenchymal Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885548.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


8. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD: Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol; 2010 Feb;12(2):164-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
  • The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]).
  • Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included.
  • Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1774-83 [16030116.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • (PMID = 20150383.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-62399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2940570
  •  go-up   go-down


9. Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, Van Meir EG: Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res; 2009 Feb 01;69(3):1212-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.
  • We recently showed that BAI1 is cleaved at a conserved proteolytic cleavage site releasing a soluble, 120 kDa antiangiogenic factor called vasculostatin (Vstat120).
  • Vstat120 has been shown to inhibit in vitro angiogenesis and suppress subcutaneous tumor growth.
  • Here, we examine its effect on the intracranial growth of malignant gliomas and further study its antitumor mechanism.
  • First, we show that expression of Vstat120 strongly suppresses the intracranial growth of malignant gliomas, even in the presence of the strong proangiogenic stimulus mediated by the oncoprotein epidermal growth factor receptor variant III (EGFRvIII).
  • This tumor-suppressive effect is accompanied by a decrease in tumor vascular density, suggesting a potent antiangiogenic effect in the brain.
  • Third, we show that these antivascular effects critically depend on the presence of the cell surface receptor CD36 on endothelial cells in vitro and in vivo, supporting the role of Vstat120 TSRs in mediating these effects.
  • These results advance the understanding of brain-specific angiogenic regulation, and suggest that Vstat120 has therapeutic potential in the treatment of brain tumors and other intracerebral vasculopathies.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Antigens, CD36 / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / therapy. Glioblastoma / blood supply. Glioblastoma / therapy. Peptide Fragments / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / physiology. Corneal Neovascularization / drug therapy. DNA, Complementary / administration & dosage. DNA, Complementary / genetics. Endothelial Cells / pathology. Humans. Mice. Mice, Nude. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / therapy. Rats. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - ADGRB1 - data and references .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Nov 1;108(9):3035-44 [16835373.001]
  • [Cites] Cancer Gene Ther. 2006 Apr;13(4):385-92 [16244591.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):454-62 [17384534.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):303-9 [17551310.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):785-91 [17786337.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):430-4 [17960134.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81 [18042934.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3932-41 [18065761.001]
  • [Cites] Mol Ther. 2008 Aug;16(8):1382-91 [18545226.001]
  • [Cites] Nat Med. 2000 Jan;6(1):41-8 [10613822.001]
  • [Cites] Int J Mol Med. 2000 Feb;5(2):181-3 [10639598.001]
  • [Cites] J Exp Med. 2000 May 15;191(10):1789-98 [10811871.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4622-7 [11274365.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Trends Mol Med. 2001 Sep;7(9):401-7 [11530335.001]
  • [Cites] Nat Med. 2002 Apr;8(4):349-57 [11927940.001]
  • [Cites] Neurosci Res. 2002 May;43(1):69-74 [12074842.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):19-27 [12507886.001]
  • [Cites] Front Biosci. 2003 May 1;8:a54-61 [12700117.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2300-5 [12727853.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Front Biosci. 2003 Sep 1;8:s874-82 [12957861.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):172-84 [14980512.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [15094109.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] J Immunol. 1992 Jan 1;148(1):78-83 [1370173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] J Cell Biol. 1992 Aug;118(3):693-701 [1379247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31 [8052651.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32 [8675406.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):310 [9139859.001]
  • [Cites] J Cell Biol. 1997 Aug 11;138(3):707-17 [9245797.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Oncogene. 1997 Oct;15(18):2145-50 [9393972.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):25-35 [9419208.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):4855-63 [9478926.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):597-604 [9647739.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):967-70 [9772287.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):34875-81 [9857015.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8603-12 [15623644.001]
  • [Cites] BMC Evol Biol. 2005;5:11 [15693998.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3632-42 [15782143.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):318-26 [16389944.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7444-55 [17189418.001]
  • (PMID = 19176395.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA150153; United States / NCI NIH HHS / CA / R01 CA086335; United States / NINDS NIH HHS / NS / R21 NS056203; United States / NHLBI NIH HHS / HL / HL67839; United States / NHLBI NIH HHS / HL / P01 HL067839; United States / NCI NIH HHS / CA / CA86335; United States / NCI NIH HHS / CA / R01 CA086335-07; United States / NINDS NIH HHS / NS / NS059575; United States / NINDS NIH HHS / NS / NS056203; United States / NHLBI NIH HHS / HL / P01 HL067839-050002; United States / NINDS NIH HHS / NS / R21 NS056203-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Antigens, CD36; 0 / BAI1 protein, human; 0 / DNA, Complementary; 0 / Peptide Fragments
  • [Other-IDs] NLM/ NIHMS81676; NLM/ PMC2659670
  •  go-up   go-down


10. Ivanov SD, Semënov AL, Kovan'ko EG, Iamshanov VA, Zabezhinskiĭ MA: [Effect of additional administration of iron ions on the efficacy of radiotherapy of glioma-bearing animals]. Vopr Onkol; 2010;56(6):692-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of additional administration of iron ions on the efficacy of radiotherapy of glioma-bearing animals].
  • Our analysis failed to establish any antitumor effect of treatment of rats with transplantable glioma-35 with iron-containing mineral drinking water (ICMW).
  • Post-irradiation administration of ICMW did not influence glioma growth significantly as compared with radiation alone.
  • Pre- and post-iradiation drinking of ICMW resulted in marked leukopenia 24 hrs after exposure as well as to significant decrease in tumor size (20-40 days after of experiment) as compared with control.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Iron, Dietary / administration & dosage
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Models, Animal. Ions / administration & dosage. Male. Neoplasms, Experimental / radiotherapy. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Rats. Time Factors. Treatment Failure. Water

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21395126.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ions; 0 / Iron, Dietary; 059QF0KO0R / Water
  •  go-up   go-down


11. Toepoel M, Joosten PHLJ, Knobbe CB, Afink GB, Zotz RB, Steegers-Theunissen RPM, Reifenberger G, van Zoelen EJJ: Haplotype-specific expression of the human PDGFRA gene correlates with the risk of glioblastomas. Int J Cancer; 2008 Jul 15;123(2):322-329
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of the platelet-derived growth factor alpha-receptor (PDGFRA) gene has been associated with various diseases, including neural tube defects and gliomas.
  • Furthermore, in 3 out of 4 available H1/H2alpha heterozygous human glioblastoma cell lines, H1-derived mRNA levels were more than 10-fold lower than from H2alpha, resulting at least in part from haplotype-specific epigenetic differences such as DNA methylation and histone acetylation.
  • Together, these results indicate that PDGFRA promoter haplotypes may predispose to gliomas.
  • We propose a model in which PDGFRA is upregulated in a haplotype-specific manner during neural stem cell differentiation, which affects the pool size of cells that can later undergo gliomagenesis.
  • [MeSH-minor] Acetylation. Adult. Aged. Case-Control Studies. DNA Methylation. Electrophoresis, Polyacrylamide Gel. Europe / epidemiology. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Haplotypes. Histones / metabolism. Humans. Incidence. Male. Middle Aged. Promoter Regions, Genetic. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18464291.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


12. Benedetti E, Galzio R, Cinque B, Biordi L, D'Amico MA, D'Angelo B, Laurenti G, Ricci A, Festuccia C, Cifone MG, Lombardi D, Cimini A: Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARgamma agonists. J Cell Physiol; 2008 Oct;217(1):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most commonly diagnosed malignant brain primary tumors.
  • Prognosis of patients with high-grade gliomas is poor and scarcely affected by radiotherapy and chemotherapy.
  • Some of these activities in cell signaling are mediated by a class of transcriptional factors referred to as peroxisome proliferator-activated receptors (PPARs).
  • PPARgamma has been identified in transformed neural cells of human origin and it has been demonstrated that PPARgamma agonists decrease cell proliferation, stimulate apoptosis and induce morphological changes and expression of markers typical of a more differentiated phenotype in glioblastoma and astrocytoma cell lines.
  • These findings arise from studies mainly performed on long-term cultured transformed cell lines.
  • [MeSH-major] Anilides / pharmacology. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Linoleic Acids, Conjugated / pharmacology. PPAR gamma / agonists
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Adhesion / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Fluorescent Antibody Technique. Humans. Neovascularization, Pathologic / metabolism. Nitric Oxide Synthase Type II / biosynthesis. Nitric Oxide Synthase Type II / drug effects. Reverse Transcriptase Polymerase Chain Reaction. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / drug effects

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18446822.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-chloro-5-nitrobenzanilide; 0 / Anilides; 0 / Linoleic Acids, Conjugated; 0 / PPAR gamma; 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


13. Giussani C, Roux FE, Ojemann J, Sganzerla EP, Pirillo D, Papagno C: Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. Neurosurgery; 2010 Jan;66(1):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies.
  • To understand the reliability of preoperative language fMRI in patients operated on for brain tumors, the surgical studies that compared language fMRI with direct cortical stimulation (DCS) were reviewed.
  • We tried to explore the effectiveness of language fMRI in gliomas.
  • The studies are not homogeneous for tumor types, magnetic fields, pre- and intraoperative language tasks, intraoperative matching criteria, and results.
  • CONCLUSION: The contradictory results of these studies do not allow consideration of language fMRI as an alternative tool to DCS in brain lesions located in language areas, especially in gliomas because of the pattern of growth of these tumors.
  • [MeSH-major] Brain Mapping. Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Cerebral Cortex. Electric Stimulation / methods. Language

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935438.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Number-of-references] 58
  •  go-up   go-down


14. Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, Kramm CM: Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer; 2010 Feb 1;116(3):705-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol.
  • BACKGROUND: The authors hypothesized that intensified chemotherapy in protocol HIT-GBM-C would increase survival of pediatric patients with high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG).
  • Overall survival rates were 91% (standard error of the mean [SE] +/- 3%), 56%, and 19% at 6, 12, and 60 months after diagnosis, respectively.
  • When compared with previous protocols, there was no significant benefit for patients with residual tumor, but the 5-year overall survival rate for patients with complete resection treated on HIT-GBM-C was 63% +/- 12% SE, compared with 17% +/- 10% SE for the historical control group (P = .003, log-rank test).
  • CONCLUSIONS: HIT-GBM-C chemotherapy after complete tumor resection was superior to previous protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy


15. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • To better define the histologic correlates of different patterns of 1p and 19q loss, we evaluated 1p/19q status in a large group of gliomas.
  • EXPERIMENTAL DESIGN: Among 205 consecutive cases of glioma studied for 1p loss of heterozygosity (LOH), 112 tumors were evaluated for both 1p and 19q LOH using at least three polymorphic markers on 1p and 19q each.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • Tumors with small segmental 1p losses (defined as LOH at some loci with retention of heterozygosity at other loci) were studied using a more extensive panel of markers to define the 1p MDR.
  • In contrast, no astrocytomas and only 6 of 30 (20%) oligoastrocytic tumors had combined 1p/19q loss.
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • Mutation analysis of the exons encoding conserved regions of CAMTA1 showed no somatic mutations in 10 gliomas, including 6 cases with and 4 cases without 1p LOH.
  • Relative to the latter, the expression level of CAMTA1 was low in oligodendroglial tumors and was further halved in cases with 1p deletion compared with those without 1p deletion (Mann-Whitney, P = 0.03).
  • CONCLUSIONS: Our data confirm the strong association of combined 1p/19q loss with classic oligodendroglioma histology and identify a very small segment of 1p36 located within CAMTA1 that was deleted in all oligodendroglial tumors with 1p LOH.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


16. Heppner PA, Sheehan JP, Steiner LE: Gamma knife surgery for low-grade gliomas. Neurosurgery; 2005 Dec;57(6):1132-9; discussion
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for low-grade gliomas.
  • OBJECT: Data regarding the long-term efficacy of Gamma knife surgery on a large series of patients with low-grade gliomas is lacking.
  • We aimed to review the outcome of patients with low-grade gliomas undergoing Gamma knife surgery at the Lars Leksell Gamma Knife Center at the University of Virginia to clarify its role in the management of these lesions.
  • Gamma knife surgery was generally performed for tumors in eloquent brain, residual tumor post-surgery or for late progression after surgery.
  • Mortality due to tumor progression occurred in 7 patients (14%).
  • CONCLUSION: Gamma knife radiosurgery is a safe treatment for low-grade gliomas and may be considered in patients with residual or recurrent disease.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Middle Aged. Nervous System Diseases / etiology. Remission Induction. Retrospective Studies. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Neurosurgery. 2008 Feb;62 Suppl 2:755-62 [18596430.001]
  • (PMID = 16331161.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, Srinivas PN, Mythili R, Rao MK, Kulkarni MJ, Hegde S, Hegde AS, Samual C, Santosh V, Singh L, Sirdeshmukh R: Differential protein expression in human gliomas and molecular insights. Proteomics; 2005 Mar;5(4):1167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential protein expression in human gliomas and molecular insights.
  • Gliomas are the most common of the primary intracranial tumors with astrocytomas constituting about 40%.
  • Using clinically and histologically assessed astrocytomas, we have studied their protein profiles using a two-dimensional gel electrophoresis-mass spectrometry approach and identified differentially expressed proteins which may be useful molecular indicators to understand these tumors.
  • A notable observation was underexpression of Prohibitin, a potential tumor suppressor protein, Rho-GDP dissociation inhibitor, Rho-GDI, a regulator of Rho GTPases and HSPs as well as destabilization of glial fibrillary acidic protein, GFAP, major protein of the glial filaments, in Grade III malignant tumors.
  • We attempt to explain glioma malignancy and progression in terms of their combined role.
  • [MeSH-major] Astrocytoma / metabolism. Electrophoresis, Gel, Two-Dimensional / methods. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Proteomics / methods
  • [MeSH-minor] Blotting, Western. Cell Proliferation. Disease Progression. Down-Regulation. Humans. Image Processing, Computer-Assisted. Mass Spectrometry. Molecular Chaperones. Neoplasms / metabolism. Trypsin / pharmacology. Up-Regulation

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759318.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Molecular Chaperones; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


18. Shooman D, Vajramani GV, Davidson J, Sparrow OC: Use of intrathecal urokinase in repeated shunt and external ventricular drain blockage from high CSF protein due to an optic pathway glioma. Childs Nerv Syst; 2010 May;26(5):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of intrathecal urokinase in repeated shunt and external ventricular drain blockage from high CSF protein due to an optic pathway glioma.
  • INTRODUCTION: High cerebrospinal fluid (CSF) protein is a recognised association of optic pathway gliomas.
  • CASE REPORT: We describe an 8-year-old boy with an optic pathway glioma, who had frequent episodes of a blocked VP shunt and EVD due to high CSF protein level.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebrospinal Fluid Proteins / adverse effects. Fibrinolytic Agents / administration & dosage. Glioma / surgery. Urokinase-Type Plasminogen Activator / administration & dosage. Ventriculoperitoneal Shunt / adverse effects

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Optic pathway glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1978 May;31(5):488-92 [649775.001]
  • [Cites] Surg Neurol. 1977 Jul;8(1):69-70 [888080.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):33-5 [9142203.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1963 Feb;26:1-26 [13976518.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):643-7 [9598681.001]
  • [Cites] Br J Neurosurg. 1996 Jun;10(3):267-73 [8799537.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1663-74 [17363519.001]
  • [Cites] Neurosurgery. 2004 Mar;54(3):577-83; discussion 583-4 [15028130.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):254-8; discussion 259 [7865412.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 May;30(5):329-33 [1699149.001]
  • [Cites] Crit Care Med. 1999 Mar;27(3):477-8 [10199523.001]
  • [Cites] J Neurosurg. 1990 Feb;72(2):245-51 [2104924.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(3):CD003692 [12137707.001]
  • [Cites] Acta Paediatr. 1995 Aug;84(8):933-6 [7488820.001]
  • (PMID = 20013278.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cerebrospinal Fluid Proteins; 0 / Fibrinolytic Agents; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


19. Funchal C, Dos Santos AQ, Jacques-Silva MC, Zamoner A, Gottfried C, Wajner M, Pessoa-Pureur R: Branched-chain alpha-keto acids accumulating in maple syrup urine disease induce reorganization of phosphorylated GFAP in C6-glioma cells. Metab Brain Dis; 2005 Sep;20(3):205-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Branched-chain alpha-keto acids accumulating in maple syrup urine disease induce reorganization of phosphorylated GFAP in C6-glioma cells.
  • In this study we investigate the effects of the branched-chain keto acids (BCKA) alpha-ketoisocaproic (KIC), alpha-ketoisovaleric (KIV), and alpha-keto-beta-methylvaleric (KMV) acids, metabolites accumulating in maple syrup urine disease (MSUD), on the in vitro phosphorylation of glial fibrillary acidic protein (GFAP) and cytoskeletal reorganization in C6-glioma cells.
  • Western Blot analysis by anti-GFAP monoclonal antibody demonstrated that BCKA were not able to alter GFAP immunocontent in total cell homogenate, but the immunocontent as well as the in vitro (32)P incorporation into GFAP recovered into the high salt Triton-insoluble cytoskeletal fraction were significantly increased.
  • Western Blot using monoclonal antiphosphoserine antibody showed that BCKA induced increased immunocontent of phosphoserine-containing amino acids in several proteins in total cell homogenate.
  • In addition, the immunocontent of phosphoserine-containing amino acids was also greatly increased in GFAP recovered in the high-salt Triton insoluble cytoskeletal fraction, corresponding to the polymerized intermedite filament (IF) proteins present in the cell.
  • [MeSH-major] Cytoskeleton / metabolism. Glial Fibrillary Acidic Protein / metabolism. Glioma / metabolism. Keto Acids / metabolism. Maple Syrup Urine Disease / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Phosphorylation. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1990 Mar 15;265(8):4722-9 [2155236.001]
  • [Cites] J Neurochem. 1994 Nov;63(5):1975-8 [7931355.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):239-43 [7952265.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Glia. 2003 Jul;43(1):87-90 [12761871.001]
  • [Cites] J Neurochem. 1986 Jul;47(1):9-17 [3011995.001]
  • [Cites] Neurochem Res. 2000 Feb;25(2):277-84 [10786713.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Dec 15;139(2):267-76 [12480141.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9 [12212801.001]
  • [Cites] Metabolism. 1961 May;10:393-402 [13775398.001]
  • [Cites] J Inherit Metab Dis. 1992;15(1):121-35 [1583867.001]
  • [Cites] Neurochem Res. 1989 Oct;14(10):941-7 [2575233.001]
  • [Cites] J Neurosci Res. 1981;6(6):741-8 [7334533.001]
  • [Cites] J Cell Biol. 1991 Mar;112(6):1205-13 [1999469.001]
  • [Cites] J Neurochem. 1987 Nov;49(5):1651-8 [3668544.001]
  • [Cites] J Comp Neurol. 1980 Oct 1;193(3):815-40 [7002963.001]
  • [Cites] J Neurochem. 1976 Apr;26(4):823-30 [987160.001]
  • [Cites] Jpn J Exp Med. 1983 Apr;53(2):109-16 [6663802.001]
  • [Cites] Metab Brain Dis. 2002 Jun;17(2):65-75 [12083338.001]
  • [Cites] J Neurol Sci. 2004 Jan 15;217(1):17-24 [14675604.001]
  • [Cites] Brain Res Brain Res Protoc. 2003 May;11(2):111-8 [12738006.001]
  • [Cites] J Cell Biol. 1989 Jun;108(6):2409-22 [2661562.001]
  • [Cites] Neuroreport. 2000 Nov 9;11(16):3545-50 [11095515.001]
  • [Cites] Glia. 2004 Nov 15;48(3):230-40 [15390119.001]
  • [Cites] Fed Proc. 1986 Jun;45(7):2060-4 [3519290.001]
  • [Cites] Metab Brain Dis. 1997 Dec;12(4):287-98 [9475502.001]
  • [Cites] Mol Genet Metab. 2004 May;82(1):69-75 [15110325.001]
  • [Cites] Int J Dev Neurosci. 1987;5(3):215-25 [3503500.001]
  • [Cites] Science. 1980 Apr 11;208(4440):179-81 [6102413.001]
  • [Cites] Brain Res. 1992 May 22;581(1):81-90 [1498672.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Pediatrics. 1964 Oct;34:454-72 [14212461.001]
  • [Cites] J Natl Cancer Inst. 1979 Mar;62(3):479-83 [216839.001]
  • (PMID = 16167198.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Keto Acids; 1460-34-0 / alpha-keto-beta-methylvaleric acid; 759-05-7 / alpha-ketoisovalerate; 816-66-0 / alpha-ketoisocaproic acid
  •  go-up   go-down


20. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E: Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol; 2010;5:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gliomas are a very rare subtype of pineal region tumours, whereas oligodendrogliomas of the pineal region are exceedingly rare, since there have been only 3 cases of anaplastic oligodedrogliomas reported this far.
  • METHODS-RESULTS: We present a case of a low-grade oligodendroglioma arising in the pineal gland of a 37 year-old woman.
  • However, the diagnosis of a low grade oligodendroglioma of the pineal gland was assigned.
  • CONCLUSION: Although the spectrum of tumours arising in the pineal gland is broad, the reports of oligodendrogliomas confined to this location are exceedingly rare, and to the best of our knowledge there is no report of a low-grade oligodendroglioma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neoplasm Staging

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1983 Jul;42(4):391-408 [6864234.001]
  • [Cites] J Morphol. 1982 Jul;173(1):73-86 [7108968.001]
  • [Cites] Surg Neurol. 1985 Feb;23(2):139-42 [3966205.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):20-30 [7821912.001]
  • [Cites] Surg Neurol. 1995 Jan;43(1):70-5; discussion 75-6 [7701429.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Brain Res. 1999 Sep 25;842(2):359-75 [10526132.001]
  • [Cites] Prog Brain Res. 1965;10:193-217 [14281603.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):80-6 [15662708.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Pathol Res Pract. 2006;202(2):85-92 [16413691.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):461-4 [16961143.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):307-14 [16645719.001]
  • [Cites] Minim Invasive Neurosurg. 2006 Aug;49(4):247-50 [17041839.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Clin Neuropathol. 2008 May-Jun;27(3):118-28 [18552083.001]
  • [Cites] J Pineal Res. 1984;1(4):323-37 [6545825.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 May;40(5):283-6 [11980097.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):223-8 [12691627.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):99-103 [7006792.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):97-102 [6739222.001]
  • (PMID = 20849631.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949720
  •  go-up   go-down


21. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M: Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci; 2009 Sep;100(9):1597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.
  • More recently, it has been revealed that ADAM17 is a potent sheddase of the epidermal growth factor (EGF) family of ligands and regulates epidermal growth factor receptor (EGFR) activity in a variety of tumors.
  • EGFR is a key component of autonomous growth signaling in several tumors, and correlates with the malignancy grade of astrocytoma.
  • Over-expression of human ADAM17 (hADAM17) in the CTX-TNA2 cortical astrocyte cell line resulted in non-adherent growth, increased proliferation, invasiveness, production of angiogenic factors, and expression of genes associated with immature and/or neoplastic cells. hADAM17 up-regulated EGFR and AKT phosphorylation, and increased proliferation and cell invasion were significantly dependent upon EGFR activity.
  • When implanted in the nude mouse brain, CTX-TNA2 cells induced low histological grade, benign intraventricular gliomas.
  • In contrast, the same astrocytes with hADAM17 formed large malignant gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2007 Dec;85(16):3523-9 [17526018.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1287-98 [17907959.001]
  • [Cites] Growth Factors. 2007 Aug;25(4):253-63 [18092233.001]
  • [Cites] World J Gastroenterol. 2008 Apr 28;14(16):2487-93 [18442194.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7 [18427106.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2821-7 [18539960.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4829-42 [18490439.001]
  • [Cites] Cell Mol Life Sci. 2008 Jul;65(14):2232-43 [18535782.001]
  • [Cites] Biol Chem. 2008 Aug;389(8):1075-84 [18979631.001]
  • [Cites] PLoS One. 2008;3(11):e3769 [19020659.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1045-54 [19395875.001]
  • [Cites] Trends Genet. 2000 Feb;16(2):83-7 [10652535.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):1-12 [12003665.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3335-9 [12067969.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1114-24 [12606576.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1324-32 [12618757.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38829-39 [12832423.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):317-29 [14724562.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1943-50 [15026328.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5283-90 [15289334.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2735-9 [15309730.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1743-53 [15509542.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6467-71 [1378628.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):77-81 [8204695.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] EMBO J. 1997 Feb 17;16(4):750-9 [9049304.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):303-14 [9440027.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43 [15688065.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):349-56 [15925591.001]
  • [Cites] J Pathol. 2005 Oct;207(2):156-63 [16041691.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):867-74 [16424019.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8083-90 [16912185.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9045-53 [16982746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14825-30 [16990429.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):337-45 [17218988.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):417-27 [17367064.001]
  • [Cites] Adv Cancer Res. 2007;97:203-24 [17419947.001]
  • [Cites] Cancer Sci. 2007 May;98(5):674-84 [17355261.001]
  • [Cites] Biochem Cell Biol. 2007 Feb;85(1):141-9 [17464354.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):30-41 [17321672.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 28;361(3):586-92 [17673180.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • (PMID = 19515085.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043892-17; United States / NCI NIH HHS / CA / R01 CA100486-04; United States / NCI NIH HHS / CA / P01 CA043892; United States / NCI NIH HHS / CA / CA100486-04; United States / NCI NIH HHS / CA / R01 CA100486; United States / NCI NIH HHS / CA / P01 CA043892-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  • [Other-IDs] NLM/ NIHMS142282; NLM/ PMC2756136
  •  go-up   go-down


22. Yaman E, Coskun U, Ozturk B, Buyukberber S, Kaya AO, Coskun O, Buyukberber N, Yildiz R, Benekli M: Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. J Clin Neurosci; 2009 Apr;16(4):591-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
  • Treatment of malignant gliomas has changed substantially over the last few years.
  • An oral alkylating agent, temozolomide, has become the standard agent for glioma management.
  • We report on a patient with malignant glioma who developed opportunistic cytomegalovirus (CMV) pneumonia following the termination of temozolomide therapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Cytomegalovirus Infections / etiology. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Opportunistic Infections / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2010 Mar;17(3):412 [20079651.001]
  • (PMID = 19201195.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Viral; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


23. Edvardsson T, Ahlström G: Illness-related problems and coping among persons with low-grade glioma. Psychooncology; 2005 Sep;14(9):728-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Illness-related problems and coping among persons with low-grade glioma.
  • The literature reveals no qualitative study concerning the consequences of low-grade glioma in adults.
  • The aim of the present study was to describe perceived illness-related problems in persons with low-grade glioma and the coping used in everyday living.
  • [MeSH-major] Adaptation, Psychological. Brain Neoplasms / psychology. Glioma / psychology. Problem Solving. Self Care. Sick Role
  • [MeSH-minor] Adult. Aged. Cross-Sectional Studies. Defense Mechanisms. Disability Evaluation. Female. Follow-Up Studies. Humans. Interview, Psychological. Male. Middle Aged. Neoplasm Staging. Personality Assessment / statistics & numerical data. Prognosis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669016.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Ziobro M, Rolski J, Grela-Wojewoda A, Zygulska A, Niemiec M: Effects of palliative treatment with temozolomide in patients with high-grade gliomas. Neurol Neurochir Pol; 2008 May-Jun;42(3):210-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
  • BACKGROUND AND PURPOSE: The aim of the study was to assess the results of treatment with temozolomide in patients with high-grade gliomas who no longer benefit from surgical treatment and radiotherapy.
  • Glioblastoma multiforme was histologically diagnosed in 24 (47%) patients; anaplastic astrocytomas and other grade III gliomas (according to WHO classification) were diagnosed in 27 (53%) patients.
  • Forty-five patients were eligible for efficacy assessment because 6 patients received only one chemotherapy cycle (due to rapid progression of the glioma).
  • RESULTS: According to the radiological assessment, 6 patients (13%) had an objective response and a further 16 patients (36%) had stabilization of the glioma.
  • The median survival in the whole group was 41 weeks (40 weeks in patients with glioblastoma multiforme and 54 weeks in patients with anaplastic gliomas).
  • CONCLUSIONS: Objective benefit from the temozolomide treatment (stabilization or objective remission) was observed in 49% of patients irrespective of histological diagnosis.
  • Tolerability of treatment with temozolomide in patients with high-grade gliomas is good.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Palliative Care / methods
  • [MeSH-minor] Adult. Disease Progression. Disease-Free Survival. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Poland. Retrospective Studies. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18651326.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


25. Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD: Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol; 2010 May 1;28(13):2293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
  • PURPOSE: To assess whether a new method of quantifying therapy-associated hemodynamic alterations may help to distinguish pseudoprogression from true progression in patients with high-grade glioma.
  • PATIENTS AND METHODS: Patients with high-grade glioma received concurrent chemoradiotherapy.
  • Pseudoprogression was defined as imaging changes 1 to 3 months after chemoradiotherapy that mimic tumor progression but stabilized or improved without change in treatment or for which resection revealed radiation effects only.
  • Of 27 patients, stable disease/partial response was noted in 13 patients and apparent progression was noted in 14 patients.
  • Based on PRM analysis, a significantly reduced blood volume (PRM(rCBV)) at week 3 was noted in patients with progressive disease as compared with those with pseudoprogression (P < .01).
  • In contrast, change in average percent rCBV or rCBF, MR tumor volume changes, age, extent of resection, and Radiation Therapy Oncology Group recursive partitioning analysis classification did not distinguish progression from pseudoprogression.
  • CONCLUSION: PRM(rCBV) at week 3 during chemoradiotherapy is a potential early imaging biomarker of response that may be helpful in distinguishing pseudoprogression from true progression in patients with high-grade glioma.


26. Angell-Petersen E, Spetalen S, Madsen SJ, Sun CH, Peng Q, Carper SW, Sioud M, Hirschberg H: Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg; 2006 Jan;104(1):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model.
  • OBJECT: Failure of treatment for high-grade gliomas is usually due to local recurrence at the site of resection, indicating that a more aggressive local therapy could be beneficial.
  • Photodynamic therapy (PDT) is a local treatment involving the administration of a tumor-localizing photosensitizing drug, in this case aminolevulinic acid (ALA).
  • METHODS: In vitro experiments showed that the sensitivity to ALA PDT of BT4C multicellular tumor spheroids depended on the rate of light delivery (fluence rate).
  • The BT4C tumors were established intracranially in BD-IX rats.
  • Microfluorometry of frozen tissue sections showed that photosensitization is produced with better than 200:1 tumor/normal tissue selectivity after ALA injection.
  • Histological examination of animals treated 14 days after tumor induction demonstrated extensive tumor necrosis after low-fluence-rate PDT, but hardly any necrosis after high-fluence-rate treatment.
  • Neutrophil infiltration in tumor tissue was increased by PDT, but was similar for both treatment regimens.
  • Low-fluence-rate PDT administered 9 days after tumor induction resulted in statistically significant prolongation of survival for treated rats compared with nontreated control animals.
  • CONCLUSIONS: Treatment with ALA PDT induced pronounced necrosis in tumors only if the light was delivered at a low rate.
  • The treatment prolonged the survival for tumor-bearing animals.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Light. Necrosis. Rats. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509154.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-62203; United States / NCRR NIH HHS / RR / RR-01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


27. Rogers G, Garside R, Mealing S, Pitt M, Anderson R, Dyer M, Stein K, Somerville M: Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. Pharmacoeconomics; 2008;26(1):33-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
  • BACKGROUND: High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively.
  • Newly diagnosed, operable grade III and IV gliomas in a population with a mean age of 55 years were considered.
  • The model incorporated utility values, obtained from members of the public, reflecting the quality of life associated with high-grade glioma.
  • CONCLUSION: Compared with usual care for the treatment of newly diagnosed high-grade gliomas, BCNU-W is unlikely to be considered a cost-effective use of healthcare resources when judged by the standards commonly adopted in England and Wales.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cohort Studies. Cost-Benefit Analysis. Drug Implants. Humans. Middle Aged. Models, Econometric. Neoplasm Staging. Quality of Life

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NCI Monogr. 1988;(6):279-84 [3281031.001]
  • [Cites] Lancet Neurol. 2005 Jul;4(7):413-22 [15963444.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):263-78 [9258818.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] BMJ. 2004 Jul 24;329(7459):224-7 [15271836.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):442-8 [8609556.001]
  • [Cites] Health Technol Assess. 2001;5(13):1-73 [11359682.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):373-7 [11861699.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Health Econ. 2001 Dec;10(8):779-87 [11747057.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Clin Trials. 1979 Spring;2(1):43-8 [229983.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Support Care Cancer. 2003 Jan;11(1):21-9 [12527950.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Med Decis Making. 1985 Summer;5(2):157-77 [3831638.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):435-43 [2541513.001]
  • [Cites] Acta Oncol. 2003;42(5-6):582-8 [14596516.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):458-66 [12959430.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] Med Decis Making. 1993 Oct-Dec;13(4):322-38 [8246705.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):917-9 [2836567.001]
  • [Cites] Int J Technol Assess Health Care. 1995 Fall;11(4):796-7 [8567213.001]
  • [Cites] BMJ. 1996 Dec 14;313(7071):1512-6 [8978225.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1175-81 [12816260.001]
  • [Cites] J Neurooncol. 1995 Nov;26(2):111-23 [8787853.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurology. 1988 Feb;38(2):284-9 [3340295.001]
  • [Cites] Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221 [17999840.001]
  • [Cites] Curr Med Res Opin. 2005 Feb;21(2):271-80 [15801998.001]
  • [Cites] Med Decis Making. 1986 Apr-Jun;6(2):85-92 [3702625.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5103-7 [2766281.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • (PMID = 18088157.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Implants; U68WG3173Y / Carmustine
  •  go-up   go-down


28. Viennet A, Nezzar H, Bonnin N, Sinardet D, Campagne D, Demeocq F, Kemeny JL, Bacin F: [An optic nerve glioma in a 4-month-old child]. J Fr Ophtalmol; 2008 Jun;31(6 Pt 1):618-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An optic nerve glioma in a 4-month-old child].
  • [Transliterated title] Gliome du nerf optique chez un enfant de 4 mois.
  • The optic nerve glioma is a relatively rare pathology in children and only a few cases have been described in infants.
  • Finally, we discuss the diagnosis and therapeutic possibilities.
  • [MeSH-major] Astrocytoma / diagnosis. Optic Nerve Glioma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Exophthalmos / etiology. Glaucoma / congenital. Glaucoma / etiology. Hemangioma, Capillary / complications. Hemangioma, Capillary / congenital. Humans. Infant. Magnetic Resonance Imaging. Male. Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neurofibromatosis 1 / diagnosis. Nose Neoplasms / complications. Nose Neoplasms / congenital. Skin Neoplasms / complications. Skin Neoplasms / congenital

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772815.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT: Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun; 2009 May 1;382(2):445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Capsaicin has been shown to have anti-carcinogenic effects on various tumor cells through multiple mechanisms.
  • Here we demonstrate that capsaicin induced downregulation of the IL-6 receptor gp130 within 2h in glial tumors.
  • These results suggest a novel mechanism for the anti-tumor effect of capsaicin.
  • [MeSH-minor] Animals. Cell Line, Tumor. Down-Regulation. Protein Biosynthesis / drug effects. Rats. Signal Transduction

  • Hazardous Substances Data Bank. CAPSAICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285962.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-6; 0 / STAT3 Transcription Factor; 133483-10-0 / Cytokine Receptor gp130; S07O44R1ZM / Capsaicin
  •  go-up   go-down


30. Valle-Argos B, Gómez-Nicola D, Nieto-Sampedro M: Glioma growth inhibition by neurostatin and O-But GD1b. Neuro Oncol; 2010 Nov;12(11):1135-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma growth inhibition by neurostatin and O-But GD1b.
  • In spite of their low incidence, central nervous system tumors have elevated morbidity and mortality, being responsible for 2.3% of total cancer deaths.
  • The ganglioside O-acetylated GD1b (O-Ac GD1b; neurostatin), present in the mammalian brain, and the semi-synthetic O-butyrylated GD1b (O-But GD1b) are potent glioma proliferation inhibitors, appearing as possible candidates for the treatment of nervous system tumors.
  • Tumoral cell division inhibitory activity in culture correlated with growth inhibition of glioma xenotransplants in Foxn1(nu) nude mice and intracranial glioma allotransplants.
  • Both O-Ac GD1b and O-But GD1b inhibited in vivo cell proliferation, induced cell cycle arrest, and potentiated immune cell response to the tumor.
  • These results are the first report of the antitumoral activity of neurostatin and a neurostatin-like compound in vivo and indicate that semi-synthetic O-acetylated and O-butyrylated gangliosides are potent antitumoral compounds that should be considered in strategies for brain tumor treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Gangliosides / pharmacology. Glioma / drug therapy. Glycosphingolipids / pharmacology
  • [MeSH-minor] Acetylation. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Separation. Flow Cytometry. Immunohistochemistry. Male. Mice. Mice, Nude. Rats. Rats, Sprague-Dawley. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Ther Targets. 2009 Jun;13(6):701-18 [19409033.001]
  • [Cites] J Neurochem. 2008 Dec;107(6):1741-52 [19014377.001]
  • [Cites] Glia. 2010 Feb;58(3):264-76 [19610094.001]
  • [Cites] Eur J Med Chem. 2010 May;45(5):2034-43 [20153569.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(12):1339-45 [10672306.001]
  • [Cites] J Neurochem. 2000 Jun;74(6):2547-56 [10820217.001]
  • [Cites] J Biochem. 2000 Jun;127(6):1021-31 [10833270.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Neuro Oncol. 1999 Oct;1(4):261-7 [11550317.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10108-13 [11796728.001]
  • [Cites] Sci STKE. 2002 Nov 26;2002(160):re15 [12454318.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2187-91 [12928361.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):418-24 [15238978.001]
  • [Cites] J Med Chem. 2004 Oct 7;47(21):4983-4 [15456241.001]
  • [Cites] J Cell Biol. 1980 Jun;85(3):890-902 [6248568.001]
  • [Cites] J Neurochem. 1980 Jul;35(1):266-9 [7452256.001]
  • [Cites] Mol Biol Med. 1983 Dec;1(5):511-29 [6094961.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3538-42 [3581087.001]
  • [Cites] Carbohydr Res. 1987 Sep 15;167:77-86 [3690578.001]
  • [Cites] Science. 1988 Jun 24;240(4860):1784-6 [3289118.001]
  • [Cites] J Neurosci Res. 1989 Jan;22(1):28-35 [2926839.001]
  • [Cites] Dev Biol. 1990 Apr;138(2):377-90 [2318341.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):25-40 [1550987.001]
  • [Cites] J Exp Med. 1992 Sep 1;176(3):915-8 [1512552.001]
  • [Cites] J Neurochem. 1993 Jul;61(1):371-4 [8515285.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):90-6 [8271027.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):851-9 [7828137.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Feb;55(2):169-77 [8786375.001]
  • [Cites] Clin Exp Immunol. 1996 Aug;105(2):344-52 [8706344.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):266-76 [9462718.001]
  • [Cites] Glia. 1998 Jun;23(2):156-68 [9600384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9142-7 [10430909.001]
  • [Cites] J Neurosci Res. 2006 Apr;83(5):754-62 [16477650.001]
  • [Cites] Glia. 2008 Apr;56(5):494-505 [18240307.001]
  • [Cites] Mol Cancer Res. 2009 Jul;7(7):1000-12 [19584260.001]
  • (PMID = 20615925.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gangliosides; 0 / Glycosphingolipids; 0 / neurostatin; 19553-76-5 / ganglioside, GD1b
  • [Other-IDs] NLM/ PMC3098019
  •  go-up   go-down


31. Assadian S, Aliaga A, Del Maestro RF, Evans AC, Bedell BJ: FDG-PET imaging for the evaluation of antiglioma agents in a rat model. Neuro Oncol; 2008 Jun;10(3):292-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the ability of small-animal PET, using the (18)F-fluoro-deoxy-D-glucose (FDG) radiotracer, to predict the TE of a number of anticancer agents in the rat C6 glioma model following 3 days of treatment.
  • Semi-quantitative measurements of changes in FDG uptake during the course of treatment (standardized uptake value response [SUV(r)]) were found to be significantly lower in tumors treated with the hypoxia-inducible factor-1alpha inhibitor YC-1 (15 mg/kg) than in tumors in the control group.
  • Quantitative immunohistochemical studies demonstrated significantly lower levels of glucose transporter-1 (GLUT-1) expression in the YC-1-treated tumors, thereby correlating with the low SUV(r) observed in this group.
  • The ability of SUV(r) to predict gold-standard outcomes of TE was further validated as YC-1-treated tumors had decreased volumes compared to control tumors.
  • As such, we successfully demonstrated the ability of FDG-PET to rapidly determine the TE of novel agents for the treatment of glioma in the preclinical phase of evaluation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glioma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2004 Jan;25(1):11-7 [15061260.001]
  • [Cites] Biochem J. 2003 Dec 1;376(Pt 2):537-44 [14531732.001]
  • [Cites] J Neurooncol. 2004 May;67(3):295-303 [15164985.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5187-201 [15297423.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1061-9 [15313402.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] J Neurooncol. 1987;4(4):403-15 [3572471.001]
  • [Cites] Radiology. 1992 Jun;183(3):643-7 [1584912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3054-7 [8159705.001]
  • [Cites] Int J Cancer. 1994 Sep 1;58(5):706-12 [8077057.001]
  • [Cites] Thromb Haemost. 2004 Nov;92(5):1099-107 [15543339.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Biomarkers. 2005 Nov;10 Suppl 1:S58-68 [16298913.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):7-13 [16328028.001]
  • [Cites] FASEB J. 2006 Mar;20(3):466-75 [16507764.001]
  • [Cites] Cell Metab. 2006 Mar;3(3):177-85 [16517405.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E24 [16709030.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E6 [16709037.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6345-52 [16778212.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1524-33 [16887936.001]
  • [Cites] Mol Imaging Biol. 2007 May-Jun;9(3):144-50 [17334852.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2785-808 [15837727.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Nov;230(10):777-84 [16246906.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Br J Biomed Sci. 2000;57(2):170-8 [10912295.001]
  • [Cites] Trends Mol Med. 2001 Aug;7(8):345-50 [11516994.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):516-25 [12671019.001]
  • [Cites] Pflugers Arch. 2003 May;446(2):248-55 [12739163.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):737-47 [12536244.001]
  • [Cites] Drug News Perspect. 2003 Jun;16(5):291-8 [12942160.001]
  • [Cites] Cancer Lett. 2004 Apr 15;207(1):1-7 [15127725.001]
  • (PMID = 18430796.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucose Transporter Type 1; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2563051
  •  go-up   go-down


32. Liu W, Dahnke H, Jordan EK, Schaeffter T, Frank JA: In vivo MRI using positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide nanoparticles. NMR Biomed; 2008 Mar;21(3):242-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated a post-processing positive-contrast technique, susceptibility-gradient mapping (SGM), and compared this approach with two pulse sequences, a gradient-compensation-based "White Marker" technique and an off-resonance-based approach, inversion recovery on-resonance water suppression (IRON), for the detection of superparamagnetic iron oxide (SPIO) nanoparticle-labeled C6 glioma cells implanted in the flanks of nude rats.
  • The SGM, White Marker and IRON positive-contrast images were acquired when the labeled C6 glioma tumors were approximately 5 mm (small), approximately 10 mm (medium) and approximately 20 mm (large) in diameter along the largest dimension to evaluate their sensitivity to the dilution of the SPIO nanoparticles as the tumor cells proliferated.
  • In vivo MRI demonstrated that all three positive-contrast techniques can produce hyperintensities in areas around the labeled flank tumors against a dark background.
  • The number of positive voxels detected around small and medium tumors was significantly greater with the SGM technique than with the White Marker and IRON techniques.
  • For large tumors, the SGM resulted in a similar number of positive voxels to the White Marker technique, and the IRON approach failed to generate positive-contrast images with a 200 Hz suppression band.
  • [MeSH-minor] Animals. Artifacts. Glioma / metabolism. Glioma / pathology. Image Processing, Computer-Assisted. Neoplasm Transplantation. Rats. Rats, Nude

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 John Wiley & Sons, Ltd.
  • (PMID = 17566968.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide
  •  go-up   go-down


33. Singhal N, Selva-Nayagam S, Brown MP: Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol; 2007 Nov;85(2):229-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide is an alkylating agent used frequently in the management of gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Brain Neoplasms / therapy. Cranial Irradiation / adverse effects. Dacarbazine / analogs & derivatives. Glioblastoma / therapy. Neutropenia / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2006 May;7(5):436-8 [16648049.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):315-8 [15735923.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):212-7 [14648028.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):1-6 [9516945.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):280-3 [16728498.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):57-61 [16645714.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 17530175.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 8
  •  go-up   go-down


34. Majchrzak H, Ładziński P, Majchrzak K, Banc K: [Surgical technique in operations for brainstem gliomas]. Neurol Neurochir Pol; 2005 Jan-Feb;39(1):69-74; discussion 75-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical technique in operations for brainstem gliomas].
  • The article presents an MRI-based classification of brainstem gliomas into focal, cervicomedullary, dorsal exophytic and diffuse ones.
  • Suboccipital, trans fourth ventricle and transcondylar approaches were applied for the removal of tumors of medulla oblongata.
  • The resection of brain stem tumors is performed by piecemeal resection and not by removal en bloc.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735993.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 20
  •  go-up   go-down


35. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, Kim KW, Jung JS: Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett; 2007 Nov 18;257(2):172-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Wnt5a operates as either a tumor suppressor or a tumor stimulator, according to tumor type.
  • We initially evaluated the expression of Wnt5a in human glioma.
  • In order to assess the role of Wnt5a on proliferation in human glioblastoma cells, we employed U87MG and GBM-05, a newly established GBM cell line.
  • GBM-05 cells formed infiltrating brain tumors after being intracerebrally transplanted into nude mice, and xenotransplanted GBM-05 cells were observed to differentiate into neuronal and astrocyte lineages.
  • Wnt5a expression in the xenotransplanted tumors was higher than that detected in the surrounding brain tissues.
  • Our data indicate that Wnt5a signaling is an important regulator in the proliferation of human glioma cells.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Proliferation. Glioblastoma / pathology. Proto-Oncogene Proteins / physiology. Wnt Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Karyotyping. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Nerve Tissue Proteins / analysis. Nestin. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709179.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins
  •  go-up   go-down


36. Hulleman E, Helin K: Molecular mechanisms in gliomagenesis. Adv Cancer Res; 2005;94:1-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioma, and in particular high-grade astrocytoma termed glioblastoma multiforme (GBM), is the most common primary tumor of the brain.
  • These pathways include growth factor-induced signal transduction routes and processes that control cell cycle progression, such as the p16-CDK4-RB and the ARF-MDM2-p53 pathways.
  • Use of novel techniques including large-scale genomics and proteomics in combination with relevant mouse models will most likely provide novel insights into the molecular mechanisms underlying glioma formation and will hopefully lead to development of treatment modalities for GBM.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / physiopathology. Glioma / classification. Signal Transduction / physiology
  • [MeSH-minor] Animals. Cell Cycle / physiology. Humans. Mice

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095998.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 155
  •  go-up   go-down


37. Wu ZC, Huang Q, Shao YX, Xue ZM, Dong J, Diao Y, Wang AD, Lan Q: [Transplantation of human glioma stem cells in nude mice with green fluorescent protein expression]. Zhonghua Yi Xue Za Zhi; 2008 Aug 26;88(33):2317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transplantation of human glioma stem cells in nude mice with green fluorescent protein expression].
  • OBJECTIVES: To investigate the possibility of transplantation of human glioma stem cells (HGSCs) in nude mice stably expressing green fluorescent protein (GFP) so as to clearly identify the incubated HGSCs from the host tissues.
  • Immunohistochemistry was used to observe the transplanted tumor.
  • Confocal fluorescence microscopy showed that the tumor cells were stained red, distinguished from the host cells distinctly in the brains bearing tumor transplanted orthotopically.
  • Orthotopic transplantation of HGSCs may be used in the investigation of tumor tissue reconstitution because of the easy identification between the transplantation tumor and host tissue.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / metabolism. Green Fluorescent Proteins / biosynthesis. Neoplastic Stem Cells / transplantation

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087690.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


38. Pavelka Z, Brichtová E, Kren L, Skotáková J, Oltová A, Slampa P, Zitterbart K, Stĕrba J: [Radiotherapy induced glioblastoma in a child previously treated for cerebellar medulloblastoma (case report and review of the literature)]. Klin Onkol; 2008;21(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas represent the most frequent radiotherapy induced ("secondary") solid tumor.
  • We present a case report of a 16 years old boy who developed cerebellar glioblastoma six years following the combined treatment for medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Cerebellar Neoplasms / radiotherapy. Glioblastoma / etiology. Medulloblastoma / radiotherapy. Neoplasms, Radiation-Induced

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


39. Julow J, Szeifert GT, Bálint K, Nyáry I, Nemes Z: Tissue response to iodine-125 interstitial brachytherapy of cerebral gliomas. Prog Neurol Surg; 2007;20:312-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue response to iodine-125 interstitial brachytherapy of cerebral gliomas.
  • The purpose of this study was to investigate histopathological changes and the role of the microglia/macrophage cell system in the therapeutic effect of iodine-125 (125I) interstitial brachytherapy on cerebral gliomas.
  • Out of a series of 60 cases harboring cerebral astrocytomas and other brain tumors treated with 125I interstitial brachytherapy, autopsy material was available in 10 cases between 0.75 and 60 months after irradiation.
  • The patients were treated with 60-Gy maximum doses at the tumor periphery.
  • Besides the routine HE and Mallory's PTAH trichrome staining, immunohistochemical reactions were carried out for CD15, CD31, CD34, CD45, CD68 (PG-M1), CPM, HAM 56 and HLA-DR antigens to study immunological characteristics of the reactive cell population around gliomas after 125I treatment.
  • The present immunohistochemical study demonstrated that the early lesions following 125I interstitial brachytherapy of gliomas are characterized by migrating macrophages apparently concerned with the removal of necrotic debris.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / surgery. Glioma / surgery. Iodine Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318000.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Iodine Radioisotopes
  •  go-up   go-down


40. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S, Ohnishi T: Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol; 2007 Apr;30(4):793-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas.
  • Malignant gliomas are characterized by active invasiveness, necrosis, and vascular proliferation.
  • Although many studies have described the relationship between tumor angiogenesis and hypoxic environment, the roles of HIF-1 in cell invasion have been barely elucidated in malignant gliomas.
  • We investigated the role of HIF-1alpha in the motile and invasive activities of human glioma cells under hypoxia.
  • Four malignant glioma cell lines, U87MG, U251MG, U373MG, and LN18, were cultured under 21 and 1% oxygen concentration.
  • Expression of HIF-1alpha under hypoxia was observed to be much higher than that under normoxia in all cell lines.
  • Introducing HIF-1alpha-targeted small interfering RNA (HIF-1alpha siRNA) into the glioma cell lines resulted in downregulation of HIF-1alpha expression, and significantly suppressed glioma cell migration in vitro.
  • Co-culture of glioma spheroids and rat brain slices showed that HIF-1alpha siRNA-transfected glioma cells failed to invade the surrounding normal brain tissue in an organotypic brain slice model.
  • In addition, under hypoxic conditions, the level of matrix metalloproteinase (MMP)-2 mRNA was upregulated, and that of tissue inhibitor of metalloproteinase (TIMP)-2 was downregulated in all glioma cell lines.
  • These findings suggest that overexpression of HIF-1alpha induced by hypoxic stress is an essential event in the activation of glioma cell motility through alteration of invasion-related molecules.
  • Targeting the HIF-1alpha molecule may be a novel therapeutic strategy for malignant gliomas.
  • [MeSH-major] Anoxia / metabolism. Brain Neoplasms / pathology. Cell Movement / genetics. Glioma / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors
  • [MeSH-minor] Down-Regulation. Humans. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332917.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Small Interfering; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


41. Myong NH, Park BJ: Malignant glioma arising at the site of an excised cerebellar hemangioblastoma after irradiation in a von Hippel-Lindau disease patient. Yonsei Med J; 2009 Aug 31;50(4):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glioma arising at the site of an excised cerebellar hemangioblastoma after irradiation in a von Hippel-Lindau disease patient.
  • We describe herein a malignant glioma arising at the site of the resected hemangioblastoma after irradiation in a patient with von Hippel-Lindau disease (VHL).
  • The patient was a 25 year-old male with multiple hemangioblastomas at the cerebellum and spinal cord, multiple pancreatic cysts and a renal cell carcinoma; he was diagnosed as having VHL disease.
  • The tumor recurred at the same site 7 years later, which was a malignant glioma with no evidence of hemangioblastoma.
  • The malignant glioma showed molecular genetic profiles of radiation-induced tumors because of its diffuse p53 immunostaining and the loss of p16 immunoreactivity.
  • To the best of our knowledge, this report is the first to show a malignant glioma that developed in a patient with VHL disease after radiation therapy at the site of an excised hemangioblastoma.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Glioma / diagnosis. Glioma / etiology. Hemangioblastoma / surgery. Radiotherapy / adverse effects. von Hippel-Lindau Disease / radiotherapy


42. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE: Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res; 2008 Jul-Aug;28(4C):2437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of valproic acid on outcome of high-grade gliomas in children.
  • BACKGROUND: Chemotherapy has limited effects in the treatment of high-grade gliomas (HGGs).
  • The response to nonsurgical treatment after 8 weeks was: complete response (CR): 0, partial response (PR): 3, stable disease (SD): 4, progressive disease (PD): 2.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751431.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


43. You Y, Pu P, Huang Q, Xia Z, Wang C, Wang G, Yu C, Yu JJ, Reed E, Li QQ: Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. Int J Oncol; 2006 May;28(5):1225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo.
  • It has been shown that telomerase activity is considerably higher in the tissue of many different cancers than in normal tissue, and that the inhibition or downregulation of telomerase activity can prevent the malignant proliferation of tumor cells.
  • Antisense oligonucleotides have been widely used in suppressing the expression of genes and, therefore, in the present research, we evaluated the effect of antisense human telomerase RNA (hTR) on glioma cell growth in vitro and in vivo.
  • We showed that antisense hTR cDNA significantly inhibited TJ905 human glioma cell proliferation in vitro and tumor growth in vivo, as determined by MTT assay and by measuring the volume of glioma in nude mice.
  • Consistent with these results, we found that telomerase activity and the mRNA levels of hTR and hTERT (human telomerase reverse transcriptase) expression were markedly decreased in tumor cells treated with antisense hTR cDNA, as assessed by TRAP (telomeric repeat amplification protocol) assay and RT-PCR (reverse transcription-polymerase chain reaction) analysis.
  • Our study conclusively demonstrates that antisense hTR effectively inhibits the growth of human glioma cells in vitro and in vivo and, thus, may be potentially used for gene therapy of malignant gliomas and other cancers.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596239.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016440; United States / NCRR NIH HHS / RR / P20RR16440-010003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / DNA Primers; 0 / RNA, Antisense; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


44. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS: Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res; 2008 Dec 1;68(23):9614-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
  • Adenovirus-mediated gene therapies against brain tumors have been limited by the difficulty in tracking glioma cells infiltrating the brain parenchyma.
  • Human umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) are particularly attractive cells for clinical use in cell-based therapies.
  • In the present study, we evaluated the tumor targeting properties and antitumor effects of UCB-MSCs as gene delivery vehicles for glioma therapy.
  • We efficiently engineered UCB-MSCs to deliver a secretable trimeric form of tumor necrosis factor-related apoptosis-inducing ligand (stTRAIL) via adenoviral transduction mediated by cell-permeable peptides.
  • We then confirmed the migratory capacity of engineered UCB-MSCs toward tumor cells by an in vitro migration assay and by in vivo injection of UCB-MSCs into the tumor mass or the opposite hemisphere of established human glioma in nude mice.
  • Moreover, in vitro coculture, experiments on Transwell plates, and in vivo survival experiments showed that MSC-based stTRAIL gene delivery has more therapeutic efficacy compared with direct injection of adenovirus encoding the stTRAIL gene into a tumor mass.
  • In vivo efficacy experiments showed that intratumoral injection of engineered UCB-MSCs (MSCs-stTRAIL) significantly inhibited tumor growth and prolonged the survival of glioma-bearing mice compared with controls.
  • These results suggest that human UCB-MSCs have potential use as effective delivery vehicles for therapeutic genes in the treatment of intracranial glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Fetal Blood / cytology. Genetic Therapy / methods. Glioma / therapy. Mesenchymal Stem Cell Transplantation / methods. Mesenchymal Stromal Cells / physiology. TNF-Related Apoptosis-Inducing Ligand / genetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Apoptosis / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Humans. Male. Mice. Mice, Nude. Transduction, Genetic. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047138.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


45. Valable S, Eddi D, Constans JM, Guillamo JS, Bernaudin M, Roussel S, Petit E: MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model. Neuro Oncol; 2009 Oct;11(5):488-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model.
  • Despite treatment efforts, the median survival in patients with glioblastoma multiforme, the most aggressive form of glioma, does not extend beyond 12-15 months.
  • One of the major pathophysiological characteristics of these tumors is their ability to induce active angiogenesis.
  • However, it has been recently proposed that although specifically targeting vascular endothelial growth factor, the main angiogenic factor, certainly leads to significant tumor regression, it could also be followed by tumor relapses.
  • Here, by using MRI and histological analysis, we studied the vascular events involved in glioma growth impairment induced by Ang2 overexpression.
  • Our results show that an increase in Ang2 expression, during the tumor growth, leads to a significant decrease in tumor growth ( approximately 86%) along with an increase in the survival median ( approximately 70%) but does not modify the tumor vascular area or cerebral blood volume.
  • However, tumor Ang2-derived blood vessels display an abnormal, enlarged morphology.
  • We show that the presence of Ang2 leads to an enhancement of tumor perfusion and a decrease in tumor vessel permeability.
  • Based on our MR image evaluations of hemodynamic tumor vessel changes, we propose that Ang2-derived tumor vessels lead to an inadequate oxygenation of the tumor tissue, leading to impairment in tumor growth.
  • [MeSH-major] Angiopoietin-2 / genetics. Brain Neoplasms / genetics. Glioma / genetics. Neovascularization, Pathologic / genetics
  • [MeSH-minor] Animals. Blotting, Western. Disease Models, Animal. Hemodynamics. Immunohistochemistry. Magnetic Resonance Imaging. Male. Rats. Rats, Inbred F344. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 24;286(5449):2511-4 [10617467.001]
  • [Cites] J Neurosci. 2006 Dec 13;26(50):13007-16 [17167090.001]
  • [Cites] Oncogene. 2000 Sep 14;19(39):4549-52 [11002428.001]
  • [Cites] Circ Res. 2000 Sep 29;87(7):603-7 [11009566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1529-38 [11121659.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):496-520 [11276094.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6248-54 [11507079.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jan;23(1):7-14 [11827869.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10 [12163646.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 [15479484.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 [15502131.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1557-70 [15509526.001]
  • [Cites] Radiology. 1993 Oct;189(1):233-8 [8372199.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1459-66 [9811337.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):3009-17 [15517909.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Acad Radiol. 2005 May;12(5):640-51 [15866139.001]
  • [Cites] FASEB J. 2005 Jun;19(8):963-5 [15802489.001]
  • [Cites] IDrugs. 2005 Sep;8(9):730-3 [16118694.001]
  • [Cites] Stroke. 2005 Sep;36(9):e83-99 [16100027.001]
  • [Cites] Nat Med. 2005 Sep;11(9):992-7 [16127434.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] J Cell Sci. 2006 Jul 1;119(Pt 13):2667-78 [16772336.001]
  • [Cites] Neoplasia. 2006 May;8(5):419-28 [16790091.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1419-25 [16908550.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11991-7 [17178898.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Magn Reson Med. 2007 Apr;57(4):680-7 [17390352.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S47-58 [17611126.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1043-56 [18615861.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):837-49 [10879735.001]
  • (PMID = 19168695.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2
  • [Other-IDs] NLM/ PMC2765339
  •  go-up   go-down


46. Wagnerova D, Jiru F, Dezortova M, Vargova L, Sykova E, Hajek M: The correlation between 1H MRS choline concentrations and MR diffusion trace values in human brain tumors. MAGMA; 2009 Feb;22(1):19-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The correlation between 1H MRS choline concentrations and MR diffusion trace values in human brain tumors.
  • OBJECTIVE: The aim of this study was to develop a method for evaluating the spatial distribution of human brain gliomas in individual subjects by evaluating the correlation between the Choline (Cho) signal intensity and the diffusion trace (Tr(ADC)) values.
  • Namely, points forming an inverse linear dependence interpreted as an area of an active tumor were observed.
  • Different types of correlations were found in grade II and III gliomas.
  • CONCLUSION: The analysis of the correlation between Cho concentrations and Tr(ADC) values on a pixel-by-pixel basis should help the regional identification of the pathological state of a tissue in patients with a glioblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Choline / analysis. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):463-75 [16763973.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neuroradiology. 2006 Sep;48(9):622-31 [16752135.001]
  • [Cites] Magn Reson Med. 1999 Jan;41(1):2-7 [10025604.001]
  • [Cites] Childs Nerv Syst. 1996 Mar;12 (3):130-5 [8697454.001]
  • [Cites] Drugs. 1997 Feb;53(2):235-44 [9028743.001]
  • [Cites] J Magn Reson Imaging. 2008 Apr;27(4):718-25 [18383265.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] J Clin Neurosci. 2005 May;12(4):416-20 [15925772.001]
  • [Cites] Neuroradiology. 1997 Jul;39(7):483-9 [9258924.001]
  • [Cites] Life Sci. 1996;58(22):1929-35 [8637421.001]
  • [Cites] Neuroradiology. 2002 Aug;44(8):656-66 [12185543.001]
  • [Cites] Radiology. 1990 Dec;177(3):633-41 [2243962.001]
  • [Cites] Surg Neurol. 1995 Aug;44(2):137-44 [7502203.001]
  • [Cites] Magn Reson Imaging. 2005 Oct;23(8):851-8 [16275423.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1593-603 [7502961.001]
  • [Cites] Radiology. 1992 Dec;185(3):675-86 [1438744.001]
  • [Cites] J Neuroimaging. 1995 Jul;5(3):157-63 [7626823.001]
  • [Cites] Neuroradiology. 2004 Aug;46(8):619-27 [15243726.001]
  • [Cites] MAGMA. 2006 Feb;19(1):1-14 [16416324.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]
  • (PMID = 18953587.001).
  • [ISSN] 1352-8661
  • [Journal-full-title] Magma (New York, N.Y.)
  • [ISO-abbreviation] MAGMA
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


47. Huang JY, Cheng YJ, Lin YP, Lin HC, Su CC, Juliano R, Yang BC: Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. J Immunol; 2010 Aug 1;185(3):1450-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dense accumulations of T cells are often found in peritumoral areas, which reduce the efficiency of contact-dependent lysis of tumor cells.
  • We demonstrate in this study that the extracellular matrix (ECM) produced by tumors can directly regulate T cell migration.
  • The transmigration rate of several T cells including peripheral blood primary T cell, Jurkat, and Molt-4 measured for glioma cells or glioma ECM was consistently low.
  • Jurkat cells showed reduced amoeba-like shape formation and delayed ERK activation when they were in contact with monolayers or ECM of glioma cells as compared with those in contact with HepG2 and MCF-7 cells.
  • Glioma cells, but not MCF-7 and HepG2 cells, expressed tenascin-C.
  • Knocking down the tenascin-C gene using the short hairpin RNA strategy converted glioma cells to a transmigration-permissive phenotype for Jurkat cells regarding ERK activation, transmigration, and amoeba-like shape formation.
  • In addition, exogenous tenascin-C protein reduced the amoeba-like shape formation and transmigration of Jurkat cells through MCF-7 and HepG2 cell monolayers.
  • A high level of tenascin-C was visualized immunohistochemically in glioma tumor tissues.
  • CD3(+) T cells were detected in the boundary tumor area and stained strongly positive for tenascin-C.
  • In summary, glioma cells can actively paralyze T cell migration by the expression of tenascin-C, representing a novel immune suppressive mechanism achieved through tumor ECM.
  • [MeSH-major] Cell Migration Inhibition / immunology. Cell Polarity / immunology. Extracellular Matrix / immunology. Glioblastoma / immunology. Immune Tolerance. T-Lymphocyte Subsets / immunology. Tenascin / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / immunology. Cells, Cultured. Enzyme Activation / genetics. Enzyme Activation / immunology. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic / immunology. Hep G2 Cells. Humans. Jurkat Cells. Microscopy, Confocal

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622113.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tenascin; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


48. Xiangsong Z, Changhong L, Weian C, Dong Z: PET Imaging of cerebral astrocytoma with 13N-ammonia. J Neurooncol; 2006 Jun;78(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Dynamic 13N-ammonia PET was performed in 25 patients with suspected cerebral gliomas or recurrent cerebral astrocytomas (19 male and 6 female patients; age range 18-64 years) detected by MRI.
  • PET images were visually inspected, and the tumor-to-white matter count (T/W) ratios and the perfusion index (PI) of the tumors were determined.
  • RESULTS: Six out of nine cases of low-grade gliomas were detected with 13N-ammonia PET, and three non-astrocytoma low-grade gliomas were not detected with 13N-ammonia PET.
  • The significant differences were observed between high-grade and low-grade gliomas with respect to both the T/W ratios and PI (T/W ratios: 5.92+/-2.27, n=11 vs. 1.66+/-0.61, n=9, P<0.01; PI: 5.22+/-1.67, n=11 vs. 1.60+/-0.54, n=9, P<0.01).
  • [MeSH-major] Ammonia. Astrocytoma / diagnostic imaging. Brain Neoplasms / diagnostic imaging. Nitrogen Isotopes. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals / pharmacokinetics. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1664-70 [11702108.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] J Neurol Sci. 1995 Sep;132(1):20-7 [8523026.001]
  • [Cites] Neuropathol Appl Neurobiol. 1982 May-Jun;8(3):227-36 [6126838.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Circulation. 1980 Jan;61(1):34-43 [7349940.001]
  • [Cites] J Magn Reson Imaging. 1996 May-Jun;6(3):437-44 [8724408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1251-61 [8985051.001]
  • [Cites] J Biol Chem. 1979 Jun 25;254(12):4982-92 [36379.001]
  • [Cites] J Nucl Med. 1976 Jun;17(6):473-9 [1262965.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] J Nucl Med. 1976 Jul;17(7):603-12 [818345.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] Br J Radiol. 1982 Nov;55(659):797-804 [6982741.001]
  • [Cites] Circulation. 1981 Jun;63(6):1259-72 [7226473.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] No To Shinkei. 1993 Apr;45(4):362-8 [8101449.001]
  • [Cites] Stroke. 1981 Sep-Oct;12(5):607-19 [7303045.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):651-69 [10517938.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Jun;16(3):205-11 [1976235.001]
  • (PMID = 16739028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrogen Isotopes; 0 / Radiopharmaceuticals; 7664-41-7 / Ammonia
  •  go-up   go-down


49. Hatiboglu MA, Wei J, Wu AS, Heimberger AB: Immune therapeutic targeting of glioma cancer stem cells. Target Oncol; 2010 Sep;5(3):217-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune therapeutic targeting of glioma cancer stem cells.
  • Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance.
  • Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC.
  • Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737294.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120813; United States / NCI NIH HHS / CA / CA120813
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS643814; NLM/ PMC4262967
  •  go-up   go-down


50. Nakagawa A, Kumabe T, Kanamori M, Saito R, Hirano T, Takayama K, Tominaga T: [Clinical application of pulsed laser-induced liquid jet: preliminary report in glioma surgery]. No Shinkei Geka; 2008 Nov;36(11):1005-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of pulsed laser-induced liquid jet: preliminary report in glioma surgery].
  • PURPOSE: Both maximum resection of tumor and preservation of fine vessels are conflicting aims, but important factors to improve outcome in glioma surgery.
  • To overcome these issues, we have developed pulsed holmium: yttrium-aluminum-garnet (YAG) laser-induced liquid jet (LILJ) for microsugical use and applied it in glioma surgery.
  • LILJ was ejected randomly toward blood vessels and tissue simultaneously after removal of arachnoid membrane by microsurgical technique, and the quality of the dissection and the visual field were evaluated in 4 patients with supratentorial glioma.
  • CONCLUSION: Present results showed that the pulsed LILJ system may safely be used for microsurgical procedures, and may be useful for glioma resection where preservation of fine vessels is required.
  • [MeSH-major] Glioma / surgery. Lasers. Microsurgery / methods. Supratentorial Neoplasms / surgery

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048919.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isotonic Solutions; 8022-63-7 / Ringer's lactate
  •  go-up   go-down


51. Yao Y, Wang X, Jin K, Zhu J, Wang Y, Xiong S, Mao Y, Zhou L: B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol; 2008 Sep;89(2):121-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells.
  • B7-H4, a newly discovered member of B7 family that negatively regulates T cell-mediated immunity, may facilitate tumor progression by undermining host immunity.
  • Recent studies show that brain tumor stem-like cells (TSCs) contribute to tumorigenesis.
  • In this study, we found that B7-H4 was expressed in cultured tumor cells from human gliomas (n = 5) and medulloblastomas (n = 3).
  • Double immunostaining indicated that B7-H4 was primarily restricted to non-dividing (Ki67(-)) cultured tumor cells.
  • Tumor cells cultured under medium conditions favoring the growth of neural stem cells were able to form primary and secondary spheres, along with expression of neural stem/progenitor cell markers.
  • Secondary glioma cells derived from CD133(+) or CD133(-) cell xenografts expressed B7-H4 as well.
  • Our data suggest B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subpopulation of brain TSCs, and CD133(-) tumor cells also have the capacity to initiate brain formation in vivo.
  • [MeSH-major] Antigens, CD80 / metabolism. Astrocytoma / pathology. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Medulloblastoma / pathology. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Aged. Animals. Antigens, CD / metabolism. Child. Female. Flow Cytometry. Humans. Ki-67 Antigen / metabolism. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Metastasis. Nerve Tissue Proteins / metabolism. Tumor Cells, Cultured. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Cell Physiol. 2005 Apr;288(4):C805-12 [15601754.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Exp Cell Res. 2005 May 15;306(1):128-41 [15878339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10388-92 [12920180.001]
  • [Cites] Clin Neuropathol. 2002 Nov-Dec;21(6):252-7 [12489673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10 ):1502-7 [17524637.001]
  • [Cites] Lung Cancer. 2006 Aug;53(2):143-51 [16782226.001]
  • [Cites] Front Biosci. 2007 Jan 01;12:2252-9 [17127461.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4650-4 [14568939.001]
  • [Cites] J Immunother. 2007 Apr;30(3):251-60 [17414316.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):871-81 [16606666.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Immunity. 2003 Jun;18(6):849-61 [12818165.001]
  • [Cites] Leukemia. 2003 Oct;17 (10 ):2049-51 [14513057.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Immunity. 2003 Jun;18(6):863-73 [12818166.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10391-6 [16798883.001]
  • (PMID = 18478183.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


52. Hoelzinger DB, Demuth T, Berens ME: Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst; 2007 Nov 7;99(21):1583-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.
  • Invasion is a defining hallmark of glioblastoma multiforme, just as metastasis characterizes other high-grade tumors.
  • Glial tumors invariably recur due to the regrowth of invasive cells, which are unaffected by standard treatment modalities.
  • Drivers of glioma invasion include autocrine signals propagated by secreted factors that signal through receptors on the tumor.
  • These secreted factors are able to diffuse through the peritumoral stroma, thereby influencing parenchymal cells that surround the tumor mass.
  • Here we describe various autocrine motility factors that are expressed by invasive glioma cells and explore the effects that they may have on normal cells present in the path of invasion.
  • Conversely, normal brain parenchymal cells secrete ligands that can stimulate receptors on invasive glioma cells and potentially facilitate glioma invasion or create a permissive microenvironment for malignant progression.
  • Parallel observations have been made for solid tumors of epithelial origin, in which parenchymal and stromal cells either support or suppress tumor invasion.
  • Most autocrine and paracrine interactions involved in glioma invasion constitute known signaling systems in stages of central nervous system development that involve the migration of precursor cells that populate the developing brain.
  • Key paracrine interactions between glioma cells and the brain microenvironment can influence glioma pathobiology and therefore contribute to its poor prognosis.
  • Current therapies for glioma that could have an impact on paracrine communication between tumors and normal cells are discussed.
  • We suggest that cells in the normal brain parenchyma be considered as potential targets for adjuvant therapies to control glioma growth because such cells are less likely to develop resistance than glioma cells.
  • [MeSH-major] Autocrine Communication. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology. Paracrine Communication
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Astrocytes / metabolism. Astrocytes / pathology. Astrocytoma / metabolism. Astrocytoma / pathology. Axons / metabolism. Axons / pathology. Glioblastoma / metabolism. Glioblastoma / pathology. Glucose-6-Phosphate Isomerase / metabolism. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Neoplasm Invasiveness. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Neurons / metabolism. Neurons / pathology. Oligodendroglia / metabolism. Oligodendroglia / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971532.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01NS42262-4
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intercellular Signaling Peptides and Proteins; EC 5.3.1.9 / Glucose-6-Phosphate Isomerase
  • [Number-of-references] 127
  •  go-up   go-down


53. Sen S, Dong M, Kumar S: Isoform-specific contributions of alpha-actinin to glioma cell mechanobiology. PLoS One; 2009 Dec 23;4(12):e8427
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoform-specific contributions of alpha-actinin to glioma cell mechanobiology.
  • Glioblastoma Multiforme (GBM) is a malignant astrocytic tumor associated with low survival rates because of aggressive infiltration of tumor cells into the brain parenchyma.
  • To probe the cellular basis of this correlation, we have suppressed expression of the nonmuscle isoforms alpha-actinin-1 and alpha-actinin-4 and examined the contribution of each isoform to the structure, mechanics, and motility of human glioma tumor cells in culture.
  • Mechanistic studies reveal a relationship between alpha-actinin and non-muscle myosin II in which depletion of either alpha-actinin isoform reduces myosin expression and maximal cell-ECM tractional forces.
  • Our results demonstrate that both alpha-actinin-1 and alpha-actinin-4 make critical and distinct contributions to cytoskeletal organization, rigidity-sensing, and motility of glioma cells, thereby yielding mechanistic insight into the observed correlation between alpha-actinin expression and GBM invasiveness in vivo.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2003 Mar 14;299(5613):1743-7 [12637748.001]
  • [Cites] Glia. 2001 Dec;36(3):375-90 [11746774.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1683-90 [12782671.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:677-95 [14570586.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Mar;282(3):C595-605 [11832345.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Mar;282(3):C606-16 [11832346.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10452-7 [12149446.001]
  • [Cites] Biophys J. 2002 Dec;83(6):3162-76 [12496086.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] Biophys J. 2004 Jan;86(1 Pt 1):617-28 [14695306.001]
  • [Cites] J Cell Biol. 2004 Feb 2;164(3):427-39 [14757754.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Jun;58(2):104-11 [15083532.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):721-9 [2116421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):383-7 [8380636.001]
  • [Cites] J Cell Sci. 1994 Jul;107 ( Pt 7):1773-82 [7983147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13661-5 [9391082.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):63-72 [9533763.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2076-82 [10232591.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):51-62 [15633123.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):198-209 [15669099.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8792-800 [16204049.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):209-15 [16247023.001]
  • [Cites] J Cell Physiol. 2006 Apr;207(1):187-94 [16288479.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 5;343(2):602-8 [16554034.001]
  • [Cites] Biophys J. 2006 May 15;90(10):3762-73 [16500961.001]
  • [Cites] Cell. 2006 Aug 25;126(4):677-89 [16923388.001]
  • [Cites] Arch Biochem Biophys. 2006 Dec 15;456(2):224-31 [17094935.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):618-22 [17936423.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Biophys J. 2007 Dec 15;93(12):4453-61 [18045965.001]
  • [Cites] J Cell Sci. 2008 Jan 1;121(Pt 1):11-8 [18096687.001]
  • [Cites] Cell Motil Cytoskeleton. 2008 Jan;65(1):12-24 [17896341.001]
  • [Cites] Cell Motil Cytoskeleton. 2008 Apr;65(4):281-94 [18200567.001]
  • [Cites] Pflugers Arch. 2008 Apr;456(1):95-100 [18231808.001]
  • [Cites] Biophys J. 2008 Apr 15;94(8):3126-36 [18192374.001]
  • [Cites] Lab Invest. 2008 Jun;88(6):602-14 [18362906.001]
  • [Cites] Mol Biol Cell. 2008 Aug;19(8):3357-68 [18495866.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5348-56 [18765526.001]
  • [Cites] Nat Cell Biol. 2008 Sep;10(9):1039-50 [19160484.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4167-74 [19435897.001]
  • [Cites] Biophys J. 2009 Jun 17;96(12):5095-102 [19527669.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):749-55 [11785963.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11100-5 [10753915.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jun;4(6):446-56 [12778124.001]
  • (PMID = 20037648.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIH HHS / OD / DP2 OD004213; United States / NIH HHS / OD / 1DP2OD004213
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 11003-00-2 / Actinin; 125361-02-6 / Vinculin; EC 3.6.4.1 / Myosins
  • [Other-IDs] NLM/ PMC2793025
  •  go-up   go-down


54. Luthra PM, Kumar R, Prakash A: Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem Biophys Res Commun; 2009 Jul 10;384(4):420-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells.
  • Docking analysis of curcumin (C1), demethoxycurcumin (C2) and bisdemethoxycurcumin (C3) with Bcl-2 illustrated that among the three curcuminoids, C2 binds more efficiently into its putative active site.
  • C1, C2 and C3 were purified from turmeric rhizomes to demonstrate the molecular mechanism of their anticancer activity on human glioma U87 cells.
  • Human glioma U87 cells treated with curcuminoids resulted in activation of Bcl-2 mediated G2 checkpoint, which was associated with the induction of G2/M arrest and apoptosis.
  • [MeSH-major] Apoptosis. Brain Neoplasms / metabolism. Curcumin / analogs & derivatives. Glioma / metabolism. Proto-Oncogene Proteins c-bcl-2 / agonists
  • [MeSH-minor] Binding Sites. Cell Line, Tumor. Cell Survival / drug effects. Down-Regulation. G2 Phase / drug effects. Humans

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422808.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 24939-17-1 / demethoxycurcumin; IT942ZTH98 / Curcumin
  •  go-up   go-down


55. Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H, Lehtolainen-Dalkilic P, Vuorio T, Määttä AM, Wirth T, Airenne KJ, Ylä-Herttuala S: Avidin fusion protein-expressing lentiviral vector for targeted drug delivery. Hum Gene Ther; 2009 Aug;20(8):871-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the main objectives of cancer therapy is to enhance the effectiveness of the drug by concentrating it at the target site and to minimize the undesired side effects to nontarget cells.
  • The results showed that lentivirus-mediated gene transfer led to long-term avidin fusion protein expression on glioma cells and that the receptor was able to bind biotinylated compounds.
  • The therapeutic efficacy of avidin fusion protein in tumor treatment was tested in vitro with biotinylated and nonbiotinylated nanoparticles loaded with paclitaxel.
  • In vivo applicability of lentivirus was studied in the BDIX rat glioma model, in which high receptor expression was detected in the tumor area.
  • [MeSH-minor] Animals. Antibodies / pharmacology. Antibody Formation / drug effects. Antibody Formation / immunology. Biotin / metabolism. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Survival / drug effects. HeLa Cells. Humans. Neutralization Tests. Rats. Serum. Transduction, Genetic. Virion / drug effects. Virion / genetics

  • Hazardous Substances Data Bank. BIOTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419273.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Recombinant Fusion Proteins; 1405-69-2 / Avidin; 6SO6U10H04 / Biotin
  •  go-up   go-down


56. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
  • PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • RESULTS: With a median follow-up of 172 weeks, 63% and 59% of patients with GBM/GS and AA/AO tumors were alive at 1 year.
  • Median overall survival for patients with GBM/GS and AA/AO tumors was 64 and 99 weeks, respectively.
  • CONCLUSION: In this single-institution phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients followed by chemotherapy is associated with a median survival that is greater than that of historical controls treated with surgery plus iodine-125 brachytherapy.
  • Administration of a fixed millicurie dose resulted in a wide range of absorbed radiation doses to the SCRC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy. Tenascin / immunology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down


57. Schenka AA, Machado CM, Grippo MC, Queiroz LS, Schenka NG, Chagas CA, Verinaud L, Brousset P, Vassallo J: Immunophenotypic and ultrastructural validation of a new human glioblastoma cell line. Cell Mol Neurobiol; 2005 Aug;25(5):929-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic and ultrastructural validation of a new human glioblastoma cell line.
  • 1. A human glioma cell line, NG97, was established by Grippo et al. in 2001 from tissue obtained from a grade III astrocytoma (WHO, 2000).
  • In this first study, the cell line grew as two morphologically distinct subpopulations: dendritic/spindle cells and small round cells.
  • The injection of NG97 cells into nude mice induced an aggressive tumor characterized by: severe cytological atypia, vascular proliferation and pseudopalisading necrosis (glioblastoma multiforme features).
  • 2. The purpose of the present study was to characterize the immunophenotype and ultrastructural aspects of this cell line, using the parental tumor, cultured cells and the xenotransplant, in order to assess its glial nature and possible divergent differentiation.
  • 3. NG97 cells and xenotransplant expressed the main neuroglial markers (GFAP, S-100 protein, NSE and Leu-7) and showed no aberrant expression of other histogenetic markers.
  • GFAP was similarly expressed in the parental tumor and in the cells in culture, but decreased in the xenotransplant.
  • The xenotransplant's ultrastructural features were those of a highly undifferentiated tumor.
  • 4. Thus, our data demonstrate that NG97 cells constitute a pure glial-committed cell line, which may prove useful as a malignant glioma model in studies addressing pathophysiological, diagnostic and therapeutic issues.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Culture Techniques / standards. Cell Line, Tumor. Glioblastoma / pathology
  • [MeSH-minor] Animals. Biomarkers. Cell Differentiation. Humans. Immunophenotyping. Mice. Mice, Nude. Microscopy, Electron. Neoplasm Transplantation. Neuroglia / cytology. Reproducibility of Results. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Neurobiol. 2001 Aug;21(4):421-8 [11775071.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):455-62 [9661048.001]
  • [Cites] CA Cancer J Clin. 1993 Sep-Oct;43(5):263-71 [8364768.001]
  • [Cites] Acta Neuropathol. 1981;53(1):21-8 [7211194.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2A):234-40 [12806502.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Sep;31(8):610-6 [8528516.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):1031-5; discussion 1036-8 [1792185.001]
  • [Cites] Acta Neurol Scand. 1985 Dec;72(6):529-49 [3913271.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):204-15 [10968706.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1295-7 [2557308.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):254-8 [6690037.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):1-21; discussion 21-2 [7708144.001]
  • [Cites] Tumori. 1986 Apr 30;72(2):163-70 [3705189.001]
  • [Cites] Curr Opin Neurol. 1997 Dec;10(6):452-8 [9425558.001]
  • [Cites] Acta Neuropathol. 1990;79(5):506-12 [2327250.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):141-7 [8699236.001]
  • [Cites] Braz J Med Biol Res. 1998 Oct;31(10):1281-4 [9876299.001]
  • [Cites] Braz J Med Biol Res. 2001 May;34(5):653-61 [11323753.001]
  • (PMID = 16133944.001).
  • [ISSN] 0272-4340
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


58. Jeong SY, Lee TH, Rhee CH, Cho AR, Il Kim B, Cheon GJ, Choi CW, Lim SM: 3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study. Nucl Med Mol Imaging; 2010 Apr;44(1):45-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study.
  • PURPOSE: The purpose of this study was to compare the uptakes and diagnostic accuracies between 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) and O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET) PET in patients with a clinical suspicion of having a recurrence of glioma after multimodality treatment.
  • Recurrences were divided again into initial low-grade glioma (LGG) and high-grade glioma (HGG).
  • CONCLUSIONS: Uptakes of FLT were different according to initial grade in patients with recurrent glioma, but those of FET were not.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899937.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042959
  • [Keywords] NOTNLM ; FET / FLT / Glioma / Initial grade / PET / Recurrence
  •  go-up   go-down


59. Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D: Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1401-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult supratentorial low-grade glioma: long-term experience at a single institution.
  • PURPOSE: To report the long-term follow-up of a cohort of adult patients with supratentorial low-grade glioma treated at a single institution.
  • Function among long-term survivors without tumor progression was good to excellent for most patients.
  • CONCLUSION: Low-grade glioma is a chronic disease, with most patients dying of their disease.
  • Survival is determined primarily by the disease factors with selection and timing of adjuvant treatments having less influence on outcome.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Disease-Free Survival. Female. Follow-Up Studies. Headache / etiology. Humans. Karnofsky Performance Status. Male. Middle Aged. Quality of Life. Regression Analysis. Salvage Therapy / methods. Seizures / etiology. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395201.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS: Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol; 2006 Jul;8(3):205-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
  • Treatment of malignant gliomas represents one of the most formidable challenges in oncology.
  • Here we demonstrate the use of a minimally invasive surgical technique, convection-enhanced delivery (CED), for local administration of a novel nanoparticle liposome containing topotecan.
  • In the rat intracranial U87MG tumor model, vascular targeting of Ls-TPT with CED was associated with reductions in laminin expression and vascular density compared to free topotecan or control treatments.
  • Larger U87MG tumors, where CED of Ls-TPT on day 12 resulted in one of six cures, indicated the necessity to cover the entire tumor with the infused therapeutic agent.
  • CED of Ls-TPT was also efficacious in the intracranial U251MG tumor model (P = 0.0005 versus control).
  • We conclude that the combination of a novel nanoparticle Ls-TPT and CED administration was very effective in treating experimental brain tumors.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Brain Res Brain Res Protoc. 2005 Dec;16(1-3):20-6 [16181805.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5303-9 [11016662.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1391-8; discussion 1398-9 [11126910.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):45-59 [11302254.001]
  • [Cites] Cell Biochem Biophys. 2000;33(2):175-80 [11325037.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):221-32 [11801563.001]
  • [Cites] J Neurosci Methods. 2006 Jun 30;154(1-2):225-32 [16472868.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):36-41 [11857382.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):557-64 [12217793.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6938-43 [12460910.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):100-3 [14679127.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):141-8 [14686734.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2572-9 [15059914.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Neurooncol. 2004 May;68(1):1-9 [15174514.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6845-8 [15466170.001]
  • [Cites] Brain Pathol. 1992 Oct;2(4):277-84 [1341963.001]
  • [Cites] J Med Chem. 1994 Jan 7;37(1):40-6 [8289200.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] J Pharm Sci. 1994 Jul;83(7):967-9 [7965676.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(5):393-403 [7634381.001]
  • [Cites] Biochemistry. 1995 Oct 24;34(42):13722-8 [7577964.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1128-45 [8584154.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2183-93 [9196130.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 2;1379(3):353-66 [9545598.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1843-9 [9816139.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):181-7 [9918217.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):411-6 [10501915.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):469-71 [13641242.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):301-5 [15735921.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Apr;107(3):207-13 [15823676.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3392-401 [15867240.001]
  • [Cites] J Neurooncol. 2005 May;73(1):57-69 [15933820.001]
  • [Cites] Exp Neurol. 2005 Nov;196(1):104-11 [16109410.001]
  • [Cites] Exp Neurol. 2005 Dec;196(2):381-9 [16197944.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • (PMID = 16723630.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54-CA90788; United States / NCI NIH HHS / CA / U54 CA090788; United States / NCI NIH HHS / CO / N01-CO-27031-16; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / P50-CA097257
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC1871954
  •  go-up   go-down


61. Fernø J, Skrede S, Vik-Mo AO, Håvik B, Steen VM: Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci; 2006;7:69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs.
  • BACKGROUND: The etiology of schizophrenia is unknown, but neurodevelopmental disturbances, myelin- and oligodendrocyte abnormalities and synaptic dysfunction have been suggested as pathophysiological factors in this severe psychiatric disorder.
  • Recently, we demonstrated that the antipsychotic drugs clozapine and haloperidol stimulate lipogenic gene expression in cultured glioma cells through activation of the sterol regulatory element-binding protein (SREBP) transcription factors.
  • We here compare the action of chlorpromazine, haloperidol, clozapine, olanzapine, risperidone and ziprasidone on SREBP activation and SREBP-controlled gene expression (ACAT2, HMGCR, HMGCS1, FDPS, SC5DL, DHCR7, LDLR, FASN and SCD1) in four CNS-relevant human cell lines.
  • Glial-like cells (GaMg glioma and CCF-STTG1 astrocytoma cell lines) displayed more pronounced drug-induced SREBP activation compared to the response in HCN2 human cortical neurons and SH-SY5Y neuroblastoma cells, indicating that antipsychotic-induced activation of lipogenesis is most prominent in glial cells.
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Gene Expression Profiling. Humans

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10647-52 [12963821.001]
  • [Cites] Neurosci Lett. 2006 Mar 13;395(3):185-90 [16324787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1738-49 [14585943.001]
  • [Cites] J Lipid Res. 2004 Aug;45(8):1375-97 [15254070.001]
  • [Cites] Anticancer Res. 1988 Jul-Aug;8(4):797-803 [3178168.001]
  • [Cites] Am J Med Genet. 1994 May 1;50(4):355-7 [8209915.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29371-4 [7961912.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1575-84 [8833906.001]
  • [Cites] J Clin Invest. 1997 Mar 1;99(5):838-45 [9062340.001]
  • [Cites] J Clin Invest. 1997 Mar 1;99(5):846-54 [9062341.001]
  • [Cites] Neuropsychopharmacology. 1997 Jun;16(6):385-98 [9165494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5987-92 [9600904.001]
  • [Cites] Am J Psychiatry. 1998 Jun;155(6):751-60 [9619146.001]
  • [Cites] Eur Neuropsychopharmacol. 1999 Mar;9(3):253-6 [10208296.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):885-90 [10360127.001]
  • [Cites] Neuroscience. 1999;91(4):1247-55 [10391432.001]
  • [Cites] Am J Psychiatry. 1999 Nov;156(11):1686-96 [10553730.001]
  • [Cites] J Lipid Res. 1999 Dec;40(12):2264-70 [10588952.001]
  • [Cites] Arch Gen Psychiatry. 2000 Jan;57(1):65-73 [10632234.001]
  • [Cites] Psychopharmacology (Berl). 2000 Jan;148(1):3-15 [10663410.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]
  • [Cites] Trends Neurosci. 2001 Aug;24(8):479-86 [11476888.001]
  • [Cites] Brain Res Bull. 2001 Jul 15;55(5):597-610 [11576756.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1354-7 [11701931.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45408-16 [11577112.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1125-31 [11994399.001]
  • [Cites] Bioessays. 2003 Jan;25(1):72-8 [12508285.001]
  • [Cites] Neuropsychopharmacology. 2003 Mar;28(3):519-26 [12629531.001]
  • [Cites] Arch Gen Psychiatry. 2003 May;60(5):443-56 [12742865.001]
  • [Cites] Arch Gen Psychiatry. 2003 Jun;60(6):553-64 [12796218.001]
  • [Cites] Biol Psychiatry. 2003 Jun 15;53(12):1075-85 [12814859.001]
  • [Cites] J Psychiatry Neurosci. 2003 Jul;28(4):275-84 [12921222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11235-40 [10500160.001]
  • [Cites] Pharmacopsychiatry. 2004 Nov;37(6):243-65 [15551191.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52772-80 [15452130.001]
  • [Cites] Mol Psychiatry. 2005 Jan;10(1):79-104 [15289815.001]
  • [Cites] Nat Neurosci. 2005 Apr;8(4):468-75 [15793579.001]
  • [Cites] Mol Cell Neurosci. 2005 Jun;29(2):190-201 [15911344.001]
  • [Cites] Pharmacogenomics J. 2005;5(5):298-304 [16027736.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]
  • (PMID = 17052361.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Sterol Regulatory Element Binding Proteins
  • [Other-IDs] NLM/ PMC1635424
  •  go-up   go-down


62. Yang YL, Motte S, Kaufman LJ: Pore size variable type I collagen gels and their interaction with glioma cells. Biomaterials; 2010 Jul;31(21):5678-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pore size variable type I collagen gels and their interaction with glioma cells.
  • To limit cell exposure to temperatures lower than physiological temperature, the putative nucleation and growth mechanism of collagen was investigated to determine the time at which gel fibril and network structure becomes independent of temperature.
  • These findings were then exploited to prepare cell-embedded gels nucleated at 22, 27, or 32 degrees C and then incubated at 37 degrees C.
  • Proof of principle studies of glioma invasion in these gels suggested pore size is a key determinant of glioma invasive speed in collagen gels.
  • [MeSH-major] Collagen Type I / chemistry. Gels / chemistry. Glioma / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Extracellular Matrix / chemistry. Extracellular Matrix / metabolism. Neoplasm Invasiveness. Porosity. Rats. Rheology. Temperature

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20430434.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Gels
  •  go-up   go-down


63. Maire JP, Huchet A, Catry-Thomas I: [Radiotherapy of adult glial tumors: new developments and perspectives]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):531-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of adult glial tumors: new developments and perspectives].
  • [Transliterated title] Radiothérapie des tumeurs gliales de l'adulte : actualités et perspectives.
  • Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors.
  • The prognosis of these tumors depends on multiple factors such as age at diagnosis, Karnofsky score, histopathology, biology and treatments.
  • Median survivals are different with regard to the tumor grade.
  • During the 1990s, temozolomide (TMZ) was specifically developed as a chemotherapy agent against primary brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy / trends

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565351.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 89
  •  go-up   go-down


64. Handler MH, Foreman NK: Pontine gliomas. J Neurosurg Pediatr; 2010 Jan;5(1):140-1; author reply 141-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pontine gliomas.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Neurosurg Pediatr. 2009 Apr;3(4):259-69 [19338403.001]
  • [CommentOn] J Neurosurg Pediatr. 2009 Apr;3(4):257; author reply 257-8 [19338402.001]
  • (PMID = 20043750.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


65. Ljubimova JY, Fujita M, Khazenzon NM, Ljubimov AV, Black KL: Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Front Biosci; 2006;11:81-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in laminin isoforms associated with brain tumor invasion and angiogenesis.
  • Here we show that during progression of glial tumors laminin-9 (alpha4beta2gamma1) is switched to laminin-8 (alpha4beta1gamma1), which is dramatically increased in glial brain tumors.
  • Laminin-8 overproduction by glial tumor cells facilitates spread of glioma.
  • Brain tumors with laminin-8 overexpression recur faster after standard treatment and patients have shorter survival time.
  • Laminin-8 may be thus used as a predictor of tumor recurrence, patient survival and as a potential molecular target for glioma therapy.
  • [MeSH-major] Basement Membrane / metabolism. Brain Neoplasms / pathology. Extracellular Matrix / metabolism. Laminin / chemistry. Neovascularization, Pathologic
  • [MeSH-minor] Animals. Biomarkers, Tumor / biosynthesis. Glioblastoma / pathology. Glioma / pathology. Humans. In Vitro Techniques. Microscopy, Fluorescence. Models, Biological. Neoplasm Invasiveness. Neoplasm Metastasis. Oligonucleotides, Antisense / chemistry. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]
  • [Cites] Clin Exp Metastasis. 2002;19(2):127-34 [11964076.001]
  • [Cites] Mol Cancer Ther. 2002 Mar;1(5):347-55 [12489851.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):985-94 [14578463.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):604-12 [15274074.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:255-84 [15473841.001]
  • [Cites] Biochemistry. 1986 Jan 28;25(2):312-8 [2937447.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Lab Invest. 1991 Jul;65(1):32-40 [2072663.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):685-701 [9151674.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):187-95 [9212909.001]
  • [Cites] Cytokine. 1997 Sep;9(9):672-81 [9325016.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):3-12 [9407626.001]
  • [Cites] Int J Cancer. 1998 Mar 16;75(6):864-72 [9506531.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):233-40; discussion 240, 246 [9507524.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):215-26 [10066093.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29130-7 [10506168.001]
  • [Cites] Int J Oncol. 2001 Feb;18(2):287-95 [11172594.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6851-5 [11156378.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R411-21 [15987446.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17550-8 [11278628.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5601-10 [11454714.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(2):159-66 [11459088.001]
  • [Cites] Methods Enzymol. 2001;340:329-40 [11494857.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5403-7 [10554005.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8 [10567494.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):56-67 [10658911.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Mar;292(3):921-8 [10688605.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9591-6 [10944225.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):239-43 [10991985.001]
  • [Cites] Lancet. 2000 Nov 18;356(9243):1728-33 [11095261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14709-14 [11106372.001]
  • [Cites] Oncol Res. 2000;12(2):107-12 [11132923.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1194-202 [11809810.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):301-21 [11813879.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):592-8 [11849778.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):9-15 [11918088.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16075-80 [12454288.001]
  • (PMID = 16146715.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123495
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin; 0 / Oligonucleotides, Antisense; 0 / laminin 8; 0 / laminin 9
  • [Number-of-references] 47
  • [Other-IDs] NLM/ NIHMS410831; NLM/ PMC3506377
  •  go-up   go-down


66. Peck KK, Bradbury MS, Hou BL, Brennan NP, Holodny AI: The role of the Supplementary Motor Area (SMA) in the execution of primary motor activities in brain tumor patients: functional MRI detection of time-resolved differences in the hemodynamic response. Med Sci Monit; 2009 Apr;15(4):MT55-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the Supplementary Motor Area (SMA) in the execution of primary motor activities in brain tumor patients: functional MRI detection of time-resolved differences in the hemodynamic response.
  • BACKGROUND: Interpreting volume of activation maps of brain tumor patients remains difficult using blood oxygenation-level dependent (BOLD) functional magnetic resonance imaging (fMRI) methods.
  • The aim of this study is to use time-resolved fMRI to investigate potential alterations in the spatially-varying and time-dependent hemodynamic response function within the supplementary motor area (SMA) and primary motor cortex (PMC) in the presence of an adjacent brain tumor, relative to normal control subjects.
  • The present study determines the utility of this approach in brain tumor patients by examining the time to peak of the BOLD hemodynamic response within the SMA and PMC.
  • RESULTS: In patients with glial tumors involving the PMC, the activation of the SMA was delayed and approached that of the PMC with time-to-peak difference between the PMC and SMA averaging 0.2 s.
  • This delay in SMA activation was seen in all patients with glial tumors involving the PMC.
  • CONCLUSIONS: The results suggest that in patients with high-grade brain tumors invading the PMC , the SMA may assume a greater role in the execution of primary motor activities, in addition to its role in executive motor planning.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hemodynamics. Motor Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333211.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


67. Samnick S, Romeike BF, Lehmann T, Israel I, Rübe C, Mautes A, Reiners C, Kirsch CM: Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas. J Nucl Med; 2009 Dec;50(12):2025-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas.
  • p-(131)I-iodo-L-phenylalanine ((131)I-IPA) is a tumor-specific amino acid derivative that demonstrated antiproliferative and tumoricidal effects on experimental gliomas.
  • This study tested the efficacy of (131)I-IPA combined with external beam photon radiotherapy as a new therapeutic approach against gliomas.
  • METHODS: Glioma cells derived from the rat F98 glioma or human Tx3868 or A1207 glioblastoma cell lines were stereotactically inoculated into the brains of Fischer 344 rats or RNU rats.
  • Tumor formation was verified radiologically.
  • On day 8, groups of glioma-bearing rats of each tumor model underwent whole-brain radiotherapy with 8 Gy, an intravenous administration of (131)I-IPA (30 MBq), or combined treatment, aiming for a total of 12 rats per group.
  • All revealed metabolically and histologically large tumor masses.
  • Combined (131)I-IPA and radiotherapy treatment significantly prolonged median survival for the syngeneic Fischer-F98 glioma model (P < 0.01) and human glioblastoma-bearing RNU rats alike (P < 0.05).
  • CONCLUSION: These data convincingly demonstrated that systemic radionuclide therapy with (131)I-IPA combined with external photon radiotherapy is a safe and highly effective treatment for experimental gliomas, which may merit a clinical trial to ascertain its potential in patients with gliomas.
  • [MeSH-major] Glioma / pathology. Glioma / radiotherapy. Phenylalanine / chemistry. Phenylalanine / therapeutic use. Photons / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Iodine Radioisotopes / chemistry. Magnetic Resonance Imaging. Male. Rats. Survival Rate

  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910430.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 47E5O17Y3R / Phenylalanine
  •  go-up   go-down


68. Gupta R, Mohindra S, Gupta K: Demyelination or low-grade glioma? A diagnostic dilemma. Surg Neurol; 2009 Apr;71(4):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demyelination or low-grade glioma? A diagnostic dilemma.
  • BACKGROUND: Demyelination is a neurologic disease, usually diagnosed on the basis of clinical symptomatology and radiologic studies.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Demyelinating Diseases / pathology. Glioma / pathology
  • [MeSH-minor] Adult. Dementia / etiology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Paresis / etiology. Predictive Value of Tests. Quadriplegia / etiology. Steroids / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291484.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


69. Begnami MD, Rushing EJ, Evangelista R, Santi M, Quezado M: Evaluation of RB gene and cyclin-dependent kinase inhibitors P21 and P27 in pleomorphic xantoastrocytoma. Int J Surg Pathol; 2006 Apr;14(2):113-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xantoastrocytoma (PXA) is a rare, circumscribed astrocytic tumor that usually occurs in the superficial cerebral hemispheres in children and young adults.
  • In diffuse gliomas, approximately one third demonstrate mutations of the RB gene.
  • Low expression level and high activity of p27 are known to constitute an independent prognostic factor in patients with malignant gliomas, while p21 expressions have variable labeling ranges.
  • Nine PXAs expressed homogeneous pRb positivity in the most nuclei of the tumor cells.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Retinoblastoma Protein / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703171.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


70. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology; 2006 Apr 25;66(8):1258-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
  • Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide.
  • Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy.
  • Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Glioma / pathology. Glioma / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Carboplatin / therapeutic use. Drug Therapy, Combination. Etoposide / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / immunology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2006 Dec 12;67(11):2089; author reply 2089 [17159134.001]
  • (PMID = 16636248.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


71. Mohapatra G, Betensky RA, Miller ER, Carey B, Gaumont LD, Engler DA, Louis DN: Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn; 2006 May;8(2):268-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization.
  • For brain tumors however, paraffin-embedded tissue blocks from small stereotactic biopsies may be the only tissue routinely available.
  • The development of methods to analyze formalin-fixed, paraffin-embedded (FFPE) material therefore has the potential to impact molecular diagnosis in a significant way.
  • To this end, we constructed a BAC array representing chromosomes 1, 7, 19, and X because 1p/19q deletion and EGFR gene amplification provide clinically relevant information for glioma diagnosis.
  • Using this approach, we analyzed a series of 28 FFPE oligodendroglial tumors for alterations of chromosomes 1, 7, and 19.
  • We also independently assayed these tumors for 1p/19q deletion by fluorescence in situ hybridization and by loss of heterozygosity analyses.
  • These results suggest that aCGH could offer an improved molecular diagnostic approach for gliomas because of its ability to detect clinically relevant molecular alterations in small FFPE specimens.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):65-71 [15681476.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1623-31 [11337360.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):359-67 [11438483.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):459-64 [11694878.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • [Cites] Biometrics. 2002 Mar;58(1):232-6 [11890320.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3636-40 [12097266.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):413-6 [12543796.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):763-70 [12598311.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Am J Pathol. 1992 Oct;141(4):777-82 [1415476.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Hum Mol Genet. 2001 Feb 1;10(3):271-82 [11159946.001]
  • (PMID = 16645215.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA106695; United States / NINDS NIH HHS / NS / NS048005; United States / NINDS NIH HHS / NS / T32 NS048005; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / CA106695; United States / NCI NIH HHS / CA / CA57683; United States / NCI NIH HHS / CA / R33 CA106695
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1HG84L3525 / Formaldehyde; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1867586
  •  go-up   go-down


72. Kashimura H, Inoue T, Ogasawara K, Beppu T, Kanbara Y, Ogawa A: Three-dimensional anisotropy contrast imaging of pontine gliomas: 2 case reports. Surg Neurol; 2007 Feb;67(2):156-9; discussion 159
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anisotropy contrast imaging of pontine gliomas: 2 case reports.
  • BACKGROUND: Magnetic resonance imaging can provide a preoperative diagnosis of pontine glioma, but the findings sometimes do not correspond with the clinical symptoms.
  • We describe 2 cases of pontine gliomas who did not present with motor and sensory disturbance.
  • CASE REPORT: Three-dimensional anisotropy contrast (3DAC) imaging was used to assess the neuronal tracts in 2 patients with pontine gliomas.
  • In contrast, 3DAC imaging obviously showed the corticospinal and spinothalamic tracts and cerebellar peduncles without destruction by tumors.
  • CONCLUSION: Three-dimensional anisotropy contrast imaging provides more information about damage to the neuronal tracts in cases of pontine gliomas than other MR imaging techniques.
  • This technique may be used for preoperative mapping of the tumor and its relationship to the tracts, thus, providing an accurate road map for tumor resection.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Contrast Media / standards. Diffusion Magnetic Resonance Imaging / methods. Glioma / pathology. Imaging, Three-Dimensional. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17254873.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


73. Blázquez C, Carracedo A, Salazar M, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M: Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology; 2008 Jan;54(1):235-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?
  • Cannabinoids, the active components of Cannabis sativa L. and their derivatives, inhibit tumor growth in laboratory animals by inducing apoptosis of tumor cells and inhibiting tumor angiogenesis.
  • It has also been reported that cannabinoids inhibit tumor cell invasiveness, but the molecular targets of this cannabinoid action remain elusive.
  • Here we evaluated the effects of cannabinoids on the expression of tissue inhibitors of metalloproteinases (TIMPs), which play critical roles in the acquisition of migrating and invasive capacities by tumor cells.
  • Local administration of Delta(9)-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated TIMP-1 expression in mice bearing subcutaneous gliomas, as determined by Western blot and immunofluorescence analyses.
  • This cannabinoid-induced inhibition of TIMP-1 expression in gliomas (i) was mimicked by JWH-133, a selective CB(2) cannabinoid receptor agonist that is devoid of psychoactive side effects, (ii) was abrogated by fumonisin B1, a selective inhibitor of ceramide synthesis de novo, and (iii) was also evident in two patients with recurrent glioblastoma multiforme (grade IV astrocytoma).
  • THC also depressed TIMP-1 expression in cultures of various human glioma cell lines as well as in primary tumor cells obtained from a glioblastoma multiforme patient.
  • As TIMP-1 up-regulation is associated with high malignancy and negative prognosis of numerous cancers, TIMP-1 down-regulation may be a hallmark of cannabinoid-induced inhibition of glioma progression.
  • [MeSH-major] Down-Regulation / physiology. Glioma / drug therapy. Glioma / physiopathology. Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Cannabinoids / therapeutic use. Cell Line, Tumor. Cell Movement / drug effects. Ceramides / biosynthesis. Dronabinol / therapeutic use. Humans. Mice. Models, Animal. RNA Interference / physiology. Rats. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675107.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC; 0 / Cannabinoids; 0 / Ceramides; 0 / Tissue Inhibitor of Metalloproteinase-1; 7J8897W37S / Dronabinol
  •  go-up   go-down


74. Ryo A, Hirai A, Nishi M, Liou YC, Perrem K, Lin SC, Hirano H, Lee SW, Aoki I: A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx. J Biol Chem; 2007 Dec 14;282(50):36671-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report in our current study that the peptidyl-prolyl isomerase Pin1 is highly overexpressed in malignant human gliomas and inhibits Daxx-mediated cellular apoptosis.
  • These results together indicate that Pin1-mediated prolyl isomerization plays an important role in the negative regulation of Daxx and thereby inhibits the oxidative stress-induced cellular apoptotic response, particularly in malignant tumor cells where Pin1 is often overexpressed.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Apoptosis. Glioma / metabolism. Neoplasm Proteins / metabolism. Nuclear Proteins / metabolism. Peptidylprolyl Isomerase / metabolism. Protein Processing, Post-Translational
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antigens, CD95 / antagonists & inhibitors. Antigens, CD95 / genetics. Antigens, CD95 / metabolism. Cell Death / drug effects. Cell Death / genetics. HeLa Cells. Humans. Hydrogen Peroxide / pharmacology. JNK Mitogen-Activated Protein Kinases / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. MAP Kinase Kinase Kinase 5 / genetics. MAP Kinase Kinase Kinase 5 / metabolism. Oxidants / pharmacology. Oxidative Stress / drug effects. Oxidative Stress / genetics. Phosphorylation / drug effects. Proteasome Endopeptidase Complex / genetics. Proteasome Endopeptidase Complex / metabolism. RNA, Small Interfering / genetics. Ubiquitin / genetics. Ubiquitin / metabolism


75. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM: Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol; 2009 Feb;11(1):59-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in low-grade glioma patients receiving temozolomide.
  • The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy.
  • Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure.
  • Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy. Outcome Assessment (Health Care). Quality of Life
  • [MeSH-minor] Adult. Aged. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Sickness Impact Profile. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1175-83 [15964709.001]
  • [Cites] Oncologist. 2006 Jun;11(6):681-93 [16794247.001]
  • [Cites] Support Care Cancer. 2006 Dec;14(12):1205-12 [16710652.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):196-202 [17546575.001]
  • [Cites] Clin J Oncol Nurs. 2007 Jun;11(3):413-8 [17623625.001]
  • [Cites] Health Qual Life Outcomes. 2003;1:79 [14678568.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):324-33; discussion 333-4 [10942005.001]
  • [Cites] J Am Acad Psychoanal. 2000 Summer;28(2):371-95 [10976429.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurol. 2002 Aug;249(8):955-60 [12195437.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):992-9 [12605978.001]
  • [Cites] Neurology. 2003 Apr 8;60(7):1113-8 [12682316.001]
  • [Cites] J Neurooncol. 2003 Jun;63(2):179-86 [12825822.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2519-24 [12829670.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1278-82 [12933936.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1715-21 [14630674.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 May;55(5):372-6 [1602310.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Ann Neurol. 1994 Jul;36(1):48-54 [8024261.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1151-61 [7850714.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Brain Lang. 1997 Mar;57(1):22-37 [9126405.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1902-9 [10023313.001]
  • [Cites] Br J Radiol. 2005 Mar;78(927):230-5 [15730987.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1236-45 [16525178.001]
  • (PMID = 18713953.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2718960
  •  go-up   go-down


76. Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol; 2007;5:89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant gliomas recur even after extensive surgery and chemo-radiotherapy.
  • Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases.
  • Induction of O6-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ.
  • Interferon-beta has been reported to suppress MGMT in an experimental glioma model.
  • After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 x 106 international units/body, followed by 5 consecutive days of 200 mg/m2 TMZ in cycles of 28 days.
  • After the second cycle the tumor decreased in size by 50% (PR).
  • The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%.
  • The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.
  • CONCLUSION: It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3354-60 [10955823.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Mar;41(3):115-9; discussion 119-20 [11372553.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):175-81 [11995819.001]
  • [Cites] J Neurosurg. 2003 Dec;99(6):1047-52 [14705733.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7573-9 [16140920.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1279-85 [16969025.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1253-60 [17089046.001]
  • [Cites] J Interferon Res. 1990 Apr;10(2):141-51 [2140395.001]
  • [Cites] J Interferon Res. 1987 Jun;7(3):301-11 [3497213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6 [7753843.001]
  • [Cites] Neurol Res. 2000 Dec;22(8):802-8 [11149242.001]
  • (PMID = 17683572.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976115
  •  go-up   go-down


77. Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, Kalani MY: The many roles of microRNAs in brain tumor biology. Neurosurg Focus; 2010 Jan;28(1):E3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The many roles of microRNAs in brain tumor biology.
  • MicroRNAs (miRNAs) are now recognized as the primary RNAs involved in the purposeful silencing of the cell's own message.
  • The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / physiopathology. MicroRNAs / physiology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing / physiology. Glioma / genetics. Glioma / physiopathology. Humans. Medulloblastoma / genetics. Medulloblastoma / physiopathology. Neurogenesis / genetics. Neurogenesis / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043718.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Number-of-references] 77
  •  go-up   go-down


78. Cavaliere R, Schiff D: Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme. Neurocrit Care; 2005;3(3):249-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Patients with high-grade gliomas are at increased risk of pulmonary embolism and deep vein thrombosis.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Pulmonary Embolism / etiology


79. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP, Children's Oncology Group: Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol; 2008 Oct;10(5):752-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
  • The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas.
  • The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):981-9 [10571206.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10691-7 [16481328.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2074-83 [11283141.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):815-9 [11937316.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3445-53 [12177105.001]
  • [Cites] Neuro Oncol. 2003 Jan;5(1):8-13 [12626128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1182-5 [12654425.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2529-36 [12829672.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):157-65 [14701778.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):751-5 [3772472.001]
  • [Cites] Ann Neurol. 1990 Feb;27(2):167-73 [2317012.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1414-21 [8339232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):197-206 [8407392.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1827-34 [8082086.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1886-9 [8083712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):85-91 [7619124.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):925-9 [9276356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] Childs Nerv Syst. 1998 Apr-May;14(4-5):167-73 [9660117.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):947-9 [10192338.001]
  • [Cites] J Clin Pharmacol. 2005 Mar;45(3):299-312 [15703365.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1281-7 [16078267.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2792-7 [16265674.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):465-74 [16133531.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1266-72 [16525181.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • (PMID = 18715950.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA 97452; United States / NCI NIH HHS / CA / UM1 CA097452
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Radiation-Sensitizing Agents; 6433A42F4F / motexafin gadolinium
  • [Other-IDs] NLM/ PMC2666252
  •  go-up   go-down


80. Setty P, Hammes J, Rothämel T, Vladimirova V, Kramm CM, Pietsch T, Waha A: A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn; 2010 Nov;12(6):750-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations of both the IDH1 and IDH2 (isocitratedehydrogenase enzyme 1 and 2) genes have recently been described in cases of human glioma.
  • Since IDH1 mutations have been associated with better clinical outcome, they are suitable predictive markers for adult glioma patients.
  • So far, there are few data regarding IDH1 mutation status in high-grade gliomas of childhood.
  • Therefore, we applied this assay to 47 pediatric high-grade glioma samples (age range 6 weeks to 23 years).
  • [MeSH-major] Biomarkers, Tumor / genetics. Glioma. Isocitrate Dehydrogenase / genetics. Mutation. Sequence Analysis, DNA / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Biochem J. 1970 Jun;118(2):253-8 [4394948.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] Blood. 1989 Dec;74(8):2629-33 [2684296.001]
  • [Cites] Prog Clin Biol Res. 1990;333:499-506 [2408063.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):71-7 [2278967.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Science. 1998 Jul 17;281(5375):363, 365 [9705713.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):203-15 [15674478.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1149-53 [19246647.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1996-8 [19765000.001]
  • [Cites] Curr Opin Oncol. 2009 Nov;21(6):537-42 [19667985.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Dec 18;390(3):547-51 [19818334.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25 [19915484.001]
  • [Cites] Cancer Res. 2010 Feb 15;70(4):1689-99 [20124482.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4085-90 [10632344.001]
  • (PMID = 20847279.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-49-2 / DNA; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ PMC2963913
  •  go-up   go-down


81. Akasaki Y, Black KL, Yu JS: T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches. Front Biosci; 2005;10:2908-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
  • Despite dramatic advances in surgical technique, imaging, and adjuvant radiotherapy or chemotherapy, the prognosis for patients with malignant glial tumors remains dismal.
  • Based on the current knowledge regarding immune responses in the healthy central nervous system (CNS) and glioma-bearing hosts, we discuss dendritic cell (DC)-based immunotherapeutic approaches for malignant gliomas and the relevance of recent clinical trials and their outcomes.
  • It is now recognized that the CNS is not an immunologically tolerated site, and clearance of arising glioma cells is a routine physiological function of the normal, non-compromised immune system.
  • To escape from immune surveillance, however, clinically apparent gliomas develop complex mechanisms that suppress tumoricidal immune responses.
  • Although the use of DCs for the treatment of glioma patients may be the most appropriate approach, an effective treatment paradigm for these tumors may eventually require the use of several types of treatment.
  • Additionally, given the heterogeneity of this disease process and an immune-refractory tumor cell population, the series use of rational multiple modalities that target different tumor characteristics may be the most effective therapeutic strategy to treat malignant gliomas.
  • [MeSH-major] Central Nervous System Neoplasms / immunology. Dendritic Cells / immunology. Glioma / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Brain Neoplasms / immunology. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Humans. Immunity, Cellular. Immunotherapy

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970545.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 118
  •  go-up   go-down


82. Tamagno I, Schiffer D: Nestin expression in reactive astrocytes of human pathology. J Neurooncol; 2006 Dec;80(3):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a series of 40 surgical specimens, including gliomas, vascular malformations, abscesses and angiomas, the glial reaction has been studied by immunohistochemistry and immunofluorescence of Nestin, GFAP and Vimentin.
  • In some lesions, glial reaction was long-lasting and astrocytes were in the same late maturation stage.
  • In other lesions, such as invading malignant gliomas, astrocytes occurred in different maturation stages.
  • In the invading tumor, developing positive astrocytes were hardly distinguishable from tumor invading astrocytes that, interestingly, were much more Nestin- than GFAP-positive.
  • In the deep tumor reactive astrocytes were no more visible.
  • The impossibility to distinguish them from tumor cells in the deep tumor legitimates the suspicion of their recruitment among tumor cells.
  • [MeSH-minor] Brain Abscess / complications. Brain Abscess / immunology. Brain Abscess / metabolism. Brain Neoplasms / complications. Brain Neoplasms / immunology. Brain Neoplasms / metabolism. Central Nervous System Vascular Malformations / complications. Central Nervous System Vascular Malformations / immunology. Central Nervous System Vascular Malformations / metabolism. Glioma / complications. Glioma / immunology. Glioma / metabolism. Hemangioma / complications. Hemangioma / immunology. Hemangioma / metabolism. Humans. Nestin

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1999 Sep 4;840(1-2):153-7 [10517963.001]
  • [Cites] Brain Res. 1988 Feb 1;466(2):201-10 [3359311.001]
  • [Cites] Annu Rev Biochem. 2004;73:749-89 [15189158.001]
  • [Cites] Glia. 2004 Sep;47(4):299-313 [15293228.001]
  • [Cites] Brain Res. 1999 Aug 14;838(1-2):1-10 [10446310.001]
  • [Cites] Int J Dev Neurosci. 1993 Apr;11(2):269-80 [7687086.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Oct;29(5):434-44 [14507335.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] Int J Dev Neurosci. 2004 Apr;22(2):73-86 [15036382.001]
  • [Cites] Neuroreport. 1994 Oct 3;5(15):1885-8 [7841369.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] Brain Res. 1997 Sep 12;768(1-2):1-9 [9369294.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Neurobiol Dis. 1995 Apr;2(2):79-85 [8980011.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23996-4006 [10446168.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1127-34 [14583753.001]
  • [Cites] J Neurosci Res. 1998 Mar 15;51(6):675-81 [9545082.001]
  • [Cites] Exp Neurol. 2002 Apr;174(2):137-49 [11922656.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] Glia. 2002 Apr 1;38(1):45-64 [11921203.001]
  • [Cites] Neurosci Lett. 2004 Mar 4;357(2):103-6 [15036585.001]
  • [Cites] Brain Res. 1984 Aug;317(2):201-9 [6383523.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Eur J Neurosci. 1997 Jan;9(1):65-75 [9042570.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):125-36 [15674474.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15 [10571412.001]
  • (PMID = 16826367.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


83. Chastagner P, Kalifa C, Doz F, Bouffet E, Gentet JC, Ruchoux MM, Bracard S, Desandes E, Frappaz D, French Society of Pediatric Oncology (SFOP) Pilot Study: Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer; 2007 Nov;49(6):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
  • BACKGROUND: To evaluate the efficacy of BCNU, cisplatin, and vincristine (BCV regimen) in a prospective nonrandomized study among newly diagnosed children with high-grade glioma.
  • Patients with residual tumor continued this regimen unless no further improvement was observed on MRI, for a maximum of six courses.
  • Out of 66 eligible patients with central pathology review, the diagnosis of high-grade glioma was confirmed in 53 cases.
  • In univariate analysis, two prognostic factors were statistically significant: extent of resection and tumor location, while macroscopic total resection was the only significant prognostic factor in the multivariate analysis.
  • CONCLUSION: This BCV regimen could not be recommended in the treatment of high-grade gliomas in children, according to its lack of efficacy and its unacceptable pulmonary toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioma / therapy
  • [MeSH-minor] Adolescent. Adult. Carmustine / adverse effects. Carmustine / therapeutic use. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. France. Humans. Lung Diseases, Interstitial / chemically induced. Lung Diseases, Interstitial / mortality. Male. Medical Oncology. Pediatrics. Pilot Projects. Prospective Studies. Societies, Medical. Survival Rate. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17096408.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


84. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V: Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand; 2007 Dec;116(6):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas.
  • OBJECTIVES: To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas.
  • MATERIALS AND METHODS: GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas.
  • CONCLUSIONS: Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas.
  • GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / blood. Glioma / blood. Glioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / metabolism. Brain / pathology. Brain / physiopathology. Cell Proliferation. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Nerve Growth Factors / analysis. Nerve Growth Factors / blood. Predictive Value of Tests. Prognosis. S100 Calcium Binding Protein beta Subunit. S100 Proteins / analysis. S100 Proteins / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986096.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins
  •  go-up   go-down


85. Edvardsson TI, Ahlström GI: Subjective quality of life in persons with low-grade glioma and their next of kin. Int J Rehabil Res; 2009 Mar;32(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subjective quality of life in persons with low-grade glioma and their next of kin.
  • Patients with low-grade glioma have a longer survival than patients with highly malignant glioma, and for this reason questions of quality of life (QoL) are of particular importance to such patients as well as to their next of kin.
  • No studies have been found in which both adult patients with low-grade glioma and their next of kin have estimated their own QoL.
  • Thirty-nine patients with low-grade glioma selected from a well-defined county population and 27 next of kin participated in the study.
  • There is a need for recurrent rehabilitation during this long-term disease, and a need to give vocational rehabilitation to support the patient's desire to have a meaningful occupation.
  • [MeSH-major] Astrocytoma / rehabilitation. Brain Neoplasms / rehabilitation. Family. Glioma / rehabilitation. Oligodendroglioma / rehabilitation. Quality of Life
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Humans. Male. Middle Aged. Surveys and Questionnaires. Survivors

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648803.001).
  • [ISSN] 1473-5660
  • [Journal-full-title] International journal of rehabilitation research. Internationale Zeitschrift für Rehabilitationsforschung. Revue internationale de recherches de réadaptation
  • [ISO-abbreviation] Int J Rehabil Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD: Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol; 2006 Jan;8(1):12-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.
  • We compare survival estimates for population-based glioma cases by using two diagnostic coding schemes, (1) the International Classification of Diseases, Oncology, second edition (ICD-O-2) as reported by the Surveillance, Epidemiology, and End Results (SEER) program and (2) central neuropathology review diagnosis based on the World Health Organization II classification.
  • Eligible cases included adults residing in the San Francisco Bay SEER Area with newly diagnosed, histologically confirmed glioma during the years 1991-1994 and 1997-1999.
  • The study group included participating subjects for whom subsequent central neuropathology review confirmed glioma.
  • This finding emphasizes the need for improvements in coding for nonglioblastoma astrocytomas to provide better population survival estimates.
  • When review diagnosis was used, younger age and resection (vs. biopsy) were statistically significant for all histology groups analyzed by multivariable Cox proportional hazard models.
  • Additional statistically significant variables were as follows: among 517 glioblastoma patients, radiation treatment and being married; among 105 AA patients, inclusion of chemotherapy in the initial treatment; and among 106 patients with nonanaplastic oligodendroglial tumors, college education.
  • Further consideration of impact of marital status, education, and other social factors in glioma survival may be warranted.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(1):46-52 [10749588.001]
  • [Cites] Can J Neurol Sci. 1998 Aug;25(3):197-201 [9706720.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):963-9 [11029499.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2447-54 [9796977.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1617-22 [9815964.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3031-5 [9865917.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2241-7 [10070294.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):581-94 [10517935.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2040-4 [16103458.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1299-308 [12973855.001]
  • [Cites] Patient Educ Couns. 1999 Jul;37(3):215-30 [14528548.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1220-3 [14973082.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2567-75 [15226324.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Eur J Epidemiol. 2004;19(6):533-40 [15330125.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):397-401 [15452452.001]
  • [Cites] J Psychosom Res. 2004 Aug;57(2):123-31; discussion 133-5 [15465065.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):240-56 [7612804.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Neurol Clin. 1996 May;14(2):273-90 [8827171.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):796-803 [9024718.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1673-7 [9135006.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • (PMID = 16443944.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES06717; United States / NIEHS NIH HHS / ES / R01 ES006717; United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / CA89032; United States / NIEHS NIH HHS / ES / ES04705; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA52689; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1871921
  •  go-up   go-down


87. Devidze N, Fujimori K, Urade Y, Pfaff DW, Mong JA: Estradiol regulation of lipocalin-type prostaglandin D synthase promoter activity: evidence for direct and indirect mechanisms. Neurosci Lett; 2010 Apr 19;474(1):17-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we have used an immortalized glioma cell line transfected with a L-PGDS reporter construct and estrogen receptor (ER) alpha and ERbeta expression plasmids to further elucidate the mechanisms underlying estradiol regulation of L-PGDS gene expression.
  • Conditioned media from estradiol treated neurons applied to the glioma cell line resulted in a significant 7-fold increase in L-PGDS promoter activity supporting the possibility that neuronal-glial interactions are involved in estradiol regulation of L-PGDS.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Endocrinology. 1999 Dec;140(12):5566-78 [10579320.001]
  • [Cites] Eur J Neurosci. 2009 Feb;29(4):795-801 [19200066.001]
  • [Cites] J Comp Neurol. 2000 Dec 4;428(1):62-78 [11058225.001]
  • [Cites] Neuroreport. 2001 May 8;12(6):1161-5 [11338184.001]
  • [Cites] Neuroscientist. 2002 Feb;8(1):12-5 [11843094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):318-23 [12518068.001]
  • [Cites] Mol Endocrinol. 2003 Feb;17(2):203-8 [12554748.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):6018-26 [12488457.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15206-11 [14638944.001]
  • [Cites] Biol Reprod. 2004 Apr;70(4):1088-95 [14668211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7677-80 [3118375.001]
  • [Cites] Arch Biochem Biophys. 1988 Feb 1;260(2):521-31 [3124755.001]
  • [Cites] FASEB J. 1991 Aug;5(11):2575-81 [1907936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9070-4 [8415655.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Oct 15;196(1):396-401 [8216319.001]
  • [Cites] FEBS Lett. 1996 Aug 19;392(1):49-53 [8769313.001]
  • [Cites] J Neuroimmunol. 1996 Dec;71(1-2):11-8 [8982097.001]
  • [Cites] J Comp Neurol. 1997 Dec 1;388(4):507-25 [9388012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14689-94 [9405674.001]
  • [Cites] Endocrinology. 1998 Dec;139(12):5267-70 [9832469.001]
  • [Cites] Neuroscience. 2005;132(2):299-311 [15802184.001]
  • [Cites] Neurotoxicology. 2005 Oct;26(5):893-903 [15922453.001]
  • [Cites] Neuroscience. 2006;138(3):967-75 [16326016.001]
  • [Cites] J Neuroimmunol. 2006 May;174(1-2):82-91 [16530273.001]
  • [Cites] Int Rev Neurobiol. 2007;82:357-72 [17678971.001]
  • [Cites] J Neurochem. 2008 Mar;104(5):1345-57 [18028337.001]
  • [Cites] Eur J Neurosci. 2008 Apr;27(7):1780-92 [18371078.001]
  • [Cites] Neurosci Lett. 2008 Jun 20;438(2):233-7 [18455872.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):983-1008 [18626065.001]
  • [Cites] Mol Pharmacol. 2000 Sep;58(3):584-90 [10953052.001]
  • (PMID = 20193744.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-085037; United States / NIMH NIH HHS / MH / MH-38273; United States / NHLBI NIH HHS / HL / R01 HL085037-02; United States / NICHD NIH HHS / HD / HD-05751; United States / NICHD NIH HHS / HD / R37 HD005751; United States / NICHD NIH HHS / HD / R01 HD005751; United States / NHLBI NIH HHS / HL / R01 HL085037-03; United States / NIMH NIH HHS / MH / R01 MH038273; United States / NHLBI NIH HHS / HL / R01 HL085037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Culture Media, Conditioned; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Lipocalins; 4TI98Z838E / Estradiol; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.2 / prostaglandin R2 D-isomerase
  • [Other-IDs] NLM/ NIHMS192867; NLM/ PMC3249404
  •  go-up   go-down


88. Mehrkens JH, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, Tonn JC, Kreth FW: The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol; 2008 May;88(1):27-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
  • OBJECTIVE: To explore prospectively the positive predictive value of O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-PET in selected patients with a magnetic resonance imaging (MRI)-based suspicion of a glioma recurrence or progression.
  • Methods Patients with a supratentorial glioma (initial World Health Organization (WHO) grade II, III or IV) were considered eligible if they had both an MRI-(new/progressive contrast-enhancing lesion) and FET-PET-based diagnosis of a recurrence/progression after various forms and combinations of irradiation and chemotherapy.
  • The positive predictive value was defined as the proportion of MRI and FET-PET findings indicating glioma recurrence/progression that also tested positive for tumour recurrence/progression after stereotactic biopsy.
  • RESULTS: Thirty-one patients with initially WHO grade II (17), WHO grade III (6), and grade IV glioma (8) were included.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / therapy. Glioma / diagnostic imaging. Glioma / therapy. Radiopharmaceuticals. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Biopsy. Cell Proliferation. Combined Modality Therapy. Disease Progression. Female. Humans. Ki-67 Antigen. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Predictive Value of Tests. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2004 Aug;45(8):1293-8 [15299051.001]
  • [Cites] Zentralbl Neurochir. 2002;63(1):23-8 [12098080.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):436-44 [7861222.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):843-51 [11773974.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Nucl Med. 2006 May;47(5):776-82 [16644747.001]
  • [Cites] J Neurosurg. 1993 May;78(5):762-6 [8385709.001]
  • [Cites] Lasers Surg Med. 2007 Jun;39(5):386-93 [17565715.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):250-2 [7876865.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):678-87 [15689365.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Nucl Med Biol. 2006 Apr;33(3):287-94 [16631076.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):542-9 [10853810.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] Acta Radiol. 2006 Oct;47(8):852-61 [17050367.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):175-81 [11995819.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13 [9541290.001]
  • [Cites] Radiology. 1986 Jan;158(1):149-55 [3940373.001]
  • [Cites] J Neurooncol. 2003 May;62(3):321-8 [12777085.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4971-3 [11431326.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] Neurosurgery. 1983 Nov;13(5):523-8 [6646379.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9 [15650870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] Nuklearmedizin. 2002 Jun;41(3):120-8 [12109031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):151-8 [17289287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):65-70 [9422559.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;73(1-4):9-14 [10853090.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70 [15248032.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):318-27 [15739561.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 [16908552.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):205-12 [9935078.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):539-45; discussion 545-6 [11534670.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):181-2 [10413182.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):418-29 [7861220.001]
  • (PMID = 18217207.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / O-(2-fluoroethyl)tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine
  •  go-up   go-down


89. Kadri H, Mawla AA, Murad L: Incidence of childhood brain tumors in Syria (1993-2002). Pediatr Neurosurg; 2005 Jul-Aug;41(4):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of childhood brain tumors in Syria (1993-2002).
  • OBJECTIVE: To determine whether the incidence and location of childhood CNS tumors in Syria follows the same pattern described in Western and Far Eastern countries.
  • PATIENTS AND METHODS: We analyzed the data compiled from 367 children with brain tumors operated on in our Department of Neurosurgery between 1993 and mid-2002.
  • We excluded all vascular and metastatic lesions and adopted the latest WHO classification in grouping all glial tumors.
  • RESULTS: We found that 47% of brain tumors were located in the supratentorial, and 53% in the infratentorial region.
  • Low-grade tumors (WHO I/II) constituted 53.5% of all lesions, and the rest were high grade tumors (WHO III/IV) 46.5%.
  • The most common tumor found in our childhood population was medulloblastoma (27.5%), followed by astrocytoma (25.8%), then craniopharyngioma (14.1%).
  • The most common tumor in the posterior fossa was medulloblastoma (53.5%), followed by astrocytoma (22.5%), then ependymoma (17%).
  • The most common tumors in the supratentorial space were astrocytoma and craniopharyngioma.
  • CONCLUSIONS: In our patient population, the incidence and distribution of CNS tumors were somehow different than those reported by authors from the Western and Far Eastern countries.
  • Whether these results are unique to Syria, or reflect a regional difference in the disease distribution between the Middle East region and the rest of the world, remains to be determined.
  • [MeSH-major] Brain Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Neurosurg. 2011;47(5):383-4 [22572635.001]
  • (PMID = 16088251.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Sinn B, Schulze J, Schroeder G, Konschak R, Freyer D, Budach V, Tinhofer I: Pifithrin-α as a potential cytoprotective agent in radiotherapy: protection of normal tissue without decreasing therapeutic efficacy in glioma cells. Radiat Res; 2010 Nov;174(5):601-10